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A B S T R A C T
Background
This is an update of a Cochrane review first published in 2004, and previously updated in 2009 (no change in conclusions). Cervical
dystonia is a frequent and disabling disorder characterised by painful involuntary head posturing. Botulinum toxin type A (BtA) is
usually considered the first line therapy for this condition, although botulinum toxin type B (BtB) is an alternative option.
Objectives
To compare the efficacy, safety and tolerability of botulinum toxin type B (BtB) versus placebo in people with cervical dystonia.
Search methods
We identified studies for inclusion in the review using the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE, reference lists of articles and conference proceedings, last run in October 2015. We ran the search from 1977 to 2015. The
search was unrestricted by language.
Selection criteria
Double-blind, parallel, randomised, placebo-controlled trials (RCTs) of BtB versus placebo in adults with cervical dystonia.
Data collection and analysis
Two independent authors assessed records, selected included studies, extracted data using a paper pro forma and evaluated the risk of
bias. We resolved disagreements by consensus or by consulting a third author. We performed one meta-analysis for the comparison BtB
versus placebo. We used random-effects models when there was heterogeneity and fixed-effect models when there was no heterogeneity.
In addition, we performed pre-specified subgroup analyses according to BtB doses and BtA previous clinical responsiveness. The primary
efficacy outcome was overall improvement on any validated symptomatic rating scale. The primary safety outcome was the number of
participants with any adverse event.
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Main results
We included four RCTs of moderate overall methodological quality, including 441 participants with cervical dystonia. Three studies
excluded participants known to have poorer response to Bt treatment, therefore including an enriched population with a higher
probability of benefiting from Bt treatment. None of the trials were independently funded. All RCTs evaluated the effect of a single
Bt treatment session using doses between 2500 U and 10,000 U. BtB was associated with an improvement of 14.7% (95% CI 9.8%
to 19.5) in the patients’ baseline clinical status as assessed by investigators, with reduction of 6.8 points in the Toronto Western
Spasmodic Torticollis Rating Scale (TWSTRS-total score) at week 4 after injection (95% CI 4.54 to 9.01). Mean difference (MD) in
TWSTRS-pain score at week 4 was 2.20 (95% CI 1.25 to 3.15). Overall, both participants and clinicians reported an improvement of
subjective clinical status. There were no differences between groups in the withdrawals rate due to adverse events or in the proportion
of participants with adverse events. However, BtB-treated patients had a 7.65 (95% CI 2.75 to 21.32) and a 6.78 (95% CI 2.42 to
19.05) increased risk of treatment-related dry mouth and dysphagia, respectively. Statistical heterogeneity between studies was low to
moderate for most outcomes. All tested dosages were efficacious against placebo without clear-cut evidence of a dose-response gradient.
However, duration of effect (time until return to baseline TWSTRS-total score) and risk of dry mouth and dysphagia were greater in the
subgroup of participants treated with higher BtB doses. Subgroup analysis showed a higher improvement with BtB among BtA-non-
responsive participants, although there were no differences in the effect size between the BtA-responsive and non-responsive subgroups.
Authors’ conclusions
A single BtB-treatment session is associated with a significant and clinically relevant reduction of cervical dystonia impairment including
severity, disability and pain, and is well tolerated, when compared with placebo. However, BtB-treated patients are at an increased risk
of dry mouth and dysphagia. There are no data from RCTs evaluating the effectiveness and safety of repeated BtB injection cycles.
There are no RCT data to allow us to draw definitive conclusions on the optimal treatment intervals and doses, usefulness of guidance
techniques for injection, and impact on quality of life.
P L A I N L A N G U A G E S U M M A R Y
Botulinum toxin for people with involuntary posturing of the head
Undesired, uncontrollable, and often painful placement of the head, a disease called cervical dystonia or spasmodic torticollis, is a
relatively uncommon condition (affecting 57 to 280 people per million) that can be very disabling and can compromise quality of life.
Mostly the cause is unknown and no cure exists. As this is typically a chronic disease, it requires long-term treatment.
Botulinum toxin (Bt) is a natural powerful chemical produced by a bacterium called Clostridium botulinum, that can cause severe
paralysis in animals and humans. It can also be used to treat many conditions, in particular those with involuntary muscle contractions,
such as cervical dystonia, by delivering intra-muscular Bt injections. There are different types of Bt, not all available for therapeutic
purposes. Bt type A (BtA) is normally the first-used treatment in cervical dystonia. However, not all patients respond to BtA injections,
and in such situations, treatment with Bt type B (BtB) is of special interest.
This update of a previous Cochrane review aimed to assess the effectiveness (reduction in severity, disability and pain) and safety of
BtB in cervical dystonia, in comparison to placebo (a pretend medicine).
We performed a literature search in October 2015 for studies that compared BtB with placebo in people with cervical dystonia.
We found four studies comparing a single BtB treatment session with placebo, including 441 participants in total.
There was moderate-quality evidence that a single BtB treatment session is efficacious when compared to placebo, improving cervical
dystonia symptoms by between 10% and 20%. This clinical benefit applies to people with both a poor and a good response to previous
BtA treatments. Both physicians and patients evaluated BtB positively. BtB-treated patients are, however, at an increased risk of dry
mouth and swallowing difficulties.
Further studies are needed to establish the long-term clinical benefit of BtB treatment, including its impact on quality of life, to evaluate
the best treatment intervals and doses, as well as to find out which people with cervical dystonia would benefit the most from BtB
treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Botulinum Neurotoxin B compared to placebo for cervical dystonia
Patient or population: adults with cervical dystonia
Settings: hospital-based, movement disorders clinics
Intervention: botulinum neurotoxin B
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Botulinum Neurotoxin
B
Overall cervical dysto-
nia improvement as as-
sessed with TWSTRS:
change f rom baseline
to week 4
(range, 0 to 85; more is
worst)
-7 -7 The mean change f rom
baseline to week 4 in
the BtB group was 6.
78 TWSTRS units higher
(4.54 higher to 9.01
higher) compared to the
placebo group
316
(3 RCTs)
⊕⊕⊕©
MODERATE 1
Proport ion of with-
drawals due to adverse
events
Study populat ion RR 0.88
(0.19 to 4.06)
440
(4 RCTs)
⊕⊕©©
LOW 2,3
14 per 1000 13 per 1000
(3 to 58)
Cervical dystonia as-
sociated pain: change
f rom baseline to week
4 as assessed with TW-
STRS
(range, 0 to 20; more is
worst)
-7 -7 The mean change f rom
baseline to week 4 in
the BtB group was 2.
41 TWSTRS units higher
(0.82 higher to 4.01
higher) compared to the
placebo group
207
(2 RCTs)
⊕⊕©©
LOW 3,4
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Subject ive change as
assessed by the pat ient
at week 4
-7 -7 The mean change at
week 4 in the BtB
group was 0.86 stan-
dard deviat ions higher
(0.61 higher to 1.1
higher) compared to the
placebo group
316
(3 RCTs)
⊕⊕⊕⊕
HIGH 1
Proport ion of part ic-
ipants with adverse
events
Study populat ion RR 1.09
(0.97 to 1.23)
186
(2 RCTs)
⊕©©©
VERY LOW 3,5,6
838 per 1000 930 per 1000
(796 to 1000)
Adverse events: dry
mouth
Study populat ion RR 7.65
(2.75 to 21.32)
438
(4 RCTs)
⊕⊕⊕⊕
HIGH 2
22 per 1000 168 per 1000
(60 to 467)
Adverse events: dys-
phagia
Study populat ion RR 6.78
(2.42 to 19.05)
438
(4 RCTs)
⊕⊕⊕⊕
HIGH 2
22 per 1000 148 per 1000
(53 to 417)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Two of 3 studies enrolled an enriched populat ion; none of the included studies had independent funding; blinding of outcome
assessment was unclear in all studies
2Three of 4 studies enrolled an enriched populat ion; none of the studies had a clearly stated independent funding; blinding of
outcome assessment was unclear in all studies; two out of 4 had an unclear random sequence generat ion
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3The total number of part icipants included was less than the number generated by a convent ional sample size calculat ion for
a single adequately powered trial
4I-squared of 58% and small overlap between conf idence intervals
5Both studies had an enriched populat ion and non-independent funding; blinding of outcome assessment was unclear in all
studies
6I-squared of 45% and there is a wide variance of point est imates between studies
7 Data were only available as the dif ference between the BtB and placebo groups
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews 2004, Issue 4 (Costa
2004), evaluating the efficacy and safety of Botulinum toxin type
B versus placebo in the treatment of cervical dystonia.
Description of the condition
See Table 1 for glossary of terms.
Dystonia is the third most common movement disorder, after
Parkinson’s disease and essential tremor, with an overall preva-
lence of 164 per million (Steeves 2012). Dystonia syndromes are a
group of disabling, painful disorders characterised by involuntary
sustained or intermittent muscle contractions causing abnormal,
often repetitive, movements or postures of the face, neck, trunk
or limbs (Albanese 2013). Dystonic movements are typically pat-
terned or twisting, and are often initiated or worsened by volun-
tary action (Albanese 2013). These neurological disorders can be
classified based on topographic distribution, including focal dys-
tonia (one body region, e.g. cervical dystonia and blepharospasm),
segmental dystonia (two or more adjacent regions, e.g. hemifacial
spasm), multifocal dystonia (two or more nonadjacent regions),
hemidystonia (ipsilateral regions) and generalised dystonia (trunk
and two or more other regions) (Albanese 2013; Tarsy 2006).
Focal dystonia is a highly disabling movement disorder, with seri-
ous functional and social impairment. Close to half of the patient
population quits work by the age of 40 or retires early due to dys-
tonia, and 10 years later, only 25% of patients are working com-
pared to 62% of the general population (Zoons 2012). Moreover,
health-related quality of life is significantly diminished, mainly
attributable to depression and anxiety, with scores comparable to
people with multiple sclerosis, Parkinson’s disease or stroke (Zoons
2012).
Cervical dystonia, also called spasmodic torticollis, is the most
common form of adult-onset focal dystonia, with estimates from
population studies ranging from 57 per million in Europe (ESDE
2000) to as high as 280 per million in the USA (Jankovic 2006).
It typically has its onset in the fifth decade (Albanese 2013), and
affects more women than men (Defazio 2013). This condition is
characterised by abnormal movements of head, neck, and shoul-
der, resulting in posturing of the head away from its normal cen-
tral position (Foltz 1959). It may present predominantly with sus-
tained abnormal posture, spasm, jerks, tremor, or a combination
of these features. Neck or shoulder pain, or both, occur in more
than 70% of patients (Chan 1991; Tarsy 2006).
Cervical dystonia can be classified according to the dominant
head position, with the most common type involving horizontal
turning, the so-called rotatory (or simple) torticollis (Chan 1991;
Albanese 2013). Other common patterns include laterocollis (tilt
to one side), retrocollis (tilt upwards resulting in neck extension)
and anterocollis (tilt downwards resulting in neck flexion). Com-
plex torticollis, a combination of these abnormal patterns, is fre-
quently found in clinical practice.
The aetiology of most forms of dystonia is still not fully under-
stood, with the exception of early-onset dystonia, for which a
hereditary aetiology is common (Balint 2015). In most cases of
focal adult-onset dystonia, such as cervical dystonia, the patho-
physiology is generally considered to result from inhibition of the
central nervous system (CNS) at multiple levels (Hallett 1998)
resulting in abnormal sensorimotor integration. Cervical dystonia
can also be secondary to brain injury, infections of the CNS, drugs
(such as levodopa or antipsychotics), toxics, vascular or neoplastic
disorders, and may also be psychogenic (i.e. functional) (Albanese
2013). Although most cases of cervical dystonia are currently clas-
sified as idiopathic, it should be observed that some may come to
be reclassified as inherited, since new gene discoveries are under
investigation (Albanese 2013; Balint 2015).
The natural course of cervical dystonia remains unclear though it
typically worsens over time. The clinical presentation is seldom
progressive to generalised dystonia, although it often extends to
contiguous body regions. For most patients, cervical dystonia is a
life-long disorder, with only about 10% undergoing spontaneous
remissions (Jahnanshani 1990).
To date, no curative or disease-modifying treatments are available
for cervical dystonia.
Description of the intervention
Botulinum toxin (Bt) is a powerful biological toxin produced by
Clostridium botulinum. The active form of botulinum toxin is
a di-chain polypeptide composed of two chains: a heavy chain
(100 kDa) and a light chain (50 kDa), and by associating with
certain auxiliary proteins (haemagglutinins and non-haemagglu-
tinins), the toxin forms a non-covalent multimeric complex of
variable size (Simpson 2004). The nontoxic proteins aid the for-
mation of neutralising antibodies, though beyond this their role
is unclear (Frevert 2010). Bt binds to peripheral cholinergic nerve
terminals of the neuromuscular junction as well as sympathetic
ganglionic, parasympathetic ganglionic and postganglionic termi-
nals (Simpson 2004). Bt, after binding to an acceptor protein, is
endocytosed at the presynaptic membrane of acetylcholine nerve
terminals (Pellizzari 1999). By action of the N-terminal on the
heavy -chain, a pore is formed on the endocytic membrane, which
permits the release of the light chain into the cytosol. This light
chain, which is a zinc protease, performs the key-action of the
botulinum toxin, by cleaving soluble N-ethylmaleimidesensitive
factor attachment receptor proteins (SNARE proteins) (Pellizzari
1999).
SNAREs are docking proteins for acetylcholine vesicles that allow
for the release of acetylcholine into the synaptic cleft (Pellizzari
1999). The overall effect of Bt is a local chemodenervation by
the temporary blockade of acetylcholine release at cholinergic
synapses. Temporary synapses are consequently formed via the
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process of axonal sprouting (Duchen 1971; Holland 1981; Juzans
1996).
There are seven immunologically distinct botulinum toxin
serotypes (labelled A toG). These different Bt serotypes cleave spe-
cific SNARE proteins. Serotype A cleaves SNARE protein SNAP
25 located on the inner membrane, and serotype B targets synap-
tobrevin located on the vesicular membrane (Pellizzari 1999).
Botulinum toxin is injected into the muscles involved in dystonia,
with or without guidance by either electromyography (EMG) or
ultrasound. As a general rule, the number of muscles injected and
the number of injection sites per muscle are tailored to the severity
of the case in question and the mass of the muscle, respectively.
Within roughly three months after injection of botulinum toxin
into skeletalmuscle, the nerve terminal resumes exocytosis, and the
muscle returns to its baseline clinical function, showing a wearing
off response from the Bt injection (Jankovic 2004). Eventually, the
muscle paralysis subsides, and this is associated with the formation
of new sprouts capable of neurotransmission. Over time, synaptic
activity resumes in the original nerve terminals, leading to sprout
regression (de Paiva 1999).
Currently there are two commercially available Bt serotypes (BtA
and BtB). The following products are commonly available (three
BtA and one BtB): onabotulinumtoxinA (Botox®, Allergan Inc.,
Irvine, CA, USA), abobotulinumtoxinA (Dysport®/Reloxin®/
Azzalure®, Ipsen Pharma, Boulogne Billancourt, France), incobo-
tulinumtoxinA (Xeomin®/Bocoture® Merz GmbH, Frankfurt,
Germany), and rimabotulinumtoxinB (Myobloc®/Neurobloc®,
Solstice Neurosciences Inc., Louisville, KY, USA). Other BtA for-
mulations are available in more restricted markets and are yet to
receive a generic name: Prosigne®/Lantox® (Lanzhou Institute of
Biological Products, China), PurTox® (Mentor Worldwide LLC,
Santa Barbara, CA,USA), andNeuronox® (Medy-Tox Inc, South
Korea) (Walker 2014).
How the intervention might work
The therapeutic potential of all Bt serotypes derives from their
ability to inhibit the release of acetylcholine from the presynaptic
nerve terminal into the synaptic cleft, causing local chemoden-
ervation (Jankovic 2004). In addition to this, recent research has
also suggested that Bt is active at multiple levels, namely sensory
nerve terminals, andmuscle spindles, which leads to a reduction in
sensory input and fewer muscle contractions (Filippi 1993;Matak
2014; Rosales 1996; Rosales 2010).
It has also been suggested that cortical reorganisation may result
from changes in the spinal cord, brainstem and central nervous
pathways (Palomar 2012). Animal research has shown the presence
of supra-therapeutic levels of Bt by way of retrograde axonal trans-
port and penetration of the central nervous system (Antonucci
2008; Boroff 1975). However, Bt has not been shown to penetrate
the blood-brain barrier in humans.
Until recently, SNARE proteins were considered the only target
molecules of Bt. Thus, it was widely accepted that the therapeutic
and toxic actions of Bt were exclusivelymediated by SNARE cleav-
age preventing the release of synaptic neurotransmitters. However,
recent studies have suggested that a number of Bt actions might
not be mediated by SNARE cleavage, specifically regarding neu-
roexocytosis, cell cycle and apoptosis, neuritogenesis and gene ex-
pression (Matak 2015). The existence of unknown Bt molecular
targets and modulation of unknown signalling pathways is a pos-
sibility that may prove to be pharmacologically relevant.
Why it is important to do this review
BtA is the toxin serotype that has been most intensively studied
and approved for the treatment of the large number of focal dys-
tonias. BtA is considered the first line therapy for cervical dystonia
and has proven to be effective in the symptomatic management
of this condition (Albanese 2013). However, not all patients have
an adequate clinical response. Primary non-response to botulinum
toxin is seen in cases where the first and subsequent treatment
cycles do not elicit a response. Cases of secondary non-response,
however, respond to initial treatment, but over the course of mul-
tiple treatment cycles, this effect wanes and is eventually lost. Sec-
ondary non-response is partially explained by the formation of
neutralising antibodies, though it is worth noting that there are
cases of secondary non-responders without positive antibody titers
(Hanna 1998; Lange 2009) as well as cases with positive titers but
with an adequate sensitivity to Bt (Brin 2008; Muller 2009). An
estimated 4% to 20% of patients develop neutralising antibodies
to the toxin (Brashear 2008; Fabbri 2015), and if secondary non-
responsiveness occurs, it is partially related to the protein load,
with higher protein load per dose generating higher antibody titers
(Benecke 2012; Frevert 2010).
When clinical non-response occurs, other Bt serotypes are impor-
tant treatment options for cervical dystonia (Cullis 2000; Eleopra
1997; Greene 1993). At the present time, BtB is the only approved
non-BtA formulation available for the treatment of cervical dys-
tonia in the United States and in the European Union.
A Cochrane systematic review previously assessed the efficacy and
safety of BtB in comparison to placebo in people with cervical
dystonia (Costa 2004). This is the second update of that review,
having been previously updated in 2009 with no changes to con-
clusions. The original review concluded that a single injection of
BtB was efficacious in comparison to placebo in the treatment
of cervical dystonia, with a greater benefit for participants who
were BtA non-responders when compared to BtA-responders, as
assessed by subgroup analysis. Three studies were included in the
original review with a total number of 308 participants enrolled.
Since the release of the original review, a new trial has been pub-
lished (Kaji 2013). Furthermore, Cochrane’s criteria for evaluating
studies’ risk of bias and evidence quality have evolved and been
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updated. Therefore, the authors consider it important to update
this review.
O B J E C T I V E S
To compare the efficacy, safety and tolerability of botulinum toxin
type B (BtB) versus placebo in people with cervical dystonia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), blinded, single or multiple
dose, parallel-designed, of any duration, assessing the efficacy or
safety, or both, of BtB treatment versus placebo in people with
cervical dystonia were eligible for inclusion in this review. We
excluded trials in which allocation was not adequately concealed.
We excluded non-parallel study designs, namely cross-over trials,
from this updated version of the review, due to uncertainty about
whether this type of study design was appropriate to study people
with cervical dystonia, as well as methodological concerns with
regards to detection and performance bias.
Types of participants
Adults (i.e.≥ 18 years of age), in any setting, with a clinical diag-
nosis made by any physician, specialist or otherwise, of idiopathic
cervical dystonia. We allowed trials enrolling participants with any
form of cervical dystonia, and additional or more widespread dys-
tonias, for inclusion. Participants could have had prior exposure
to BtA or BtB, and could be taking any concomitant medications
if on stable regimens.
There were no restrictions regarding the number of participants
recruited to trials, or the number of recruitment centres.
Types of interventions
Intramuscular injections of BtB compared to placebo.We allowed
all administration schedules and injection techniques, performed
with or without guidance by either EMG or echography.
Types of outcome measures
Primary outcomes
Primary efficacy outcome
Overall improvement on any validated symptomatic rating scale,
such as Cervical Dystonia Severity Scale (CDSS), Tsui scale, and
Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS),
measured between weeks 3 and 6.
Primary safety outcome
Number of participants with any adverse event, measured at any
point during study follow up.
Secondary outcomes
1. Change in subjective evaluation of clinical status evaluated
by both patients and clinicians, as assessed with validated
assessment tools such as Patient Subjective Assessment of
Change, Patient Global Assessment of Improvement, Patient
Evaluation of Global Response (PEGR), Patient and Physician
Global Assessment of Change, Investigator Global Assessment of
Efficacy (IGAE), and Physician Global Assessment of Change
(PGAC), and Visual analogue scale (VAS) for symptom severity,
measured between weeks 3 and 6.
2. Changes in pain scores, as assessed with validated
assessment tools such as Patient Assessment of Pain, TWSTRS
Pain sub-scale score, and VAS Pain score, measured between
weeks 3 and 6.
3. Changes in quality- of- life assessments, as assessed with
validated assessment tools such as Short Form 36 (SF-36)
Quality-of-Life questionnaire, measured at any point during
study follow up.
4. Number of withdrawals due to adverse events, including
adverse events caused by the intervention (type A or type B, or
both, adverse drug reactions (ADRs)), and failure of therapy
(type F ADRs), measured at any point during study follow up.
5. Number of participants with adverse events of special
interest, such as dry mouth, neck weakness, dysphagia, pain at
the injection site, voice change, and systemic complaints (e.g.
diffuse muscle weakness, malaise, dizziness and headache),
measured at any point during study follow up.
6. Duration of effect, assessed by the number of days until
need for reinjection or effect waning.
Search methods for identification of studies
For this update, we expanded the search strategy to capture all the
search terms for BtB formulations that were available at the time
of the search. We designed the search strategy to include other
botulinum toxin formulations and other dystonic disorders that
were also under revision by this author team.
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Electronic searches
In October 2015 we searched the following databases.
1. Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2015, Issue 11);
2. MEDLINE (1977 to October 2015)
3. EMBASE (1977 to October 2015)
We assessed non-English language papers equally, translated them
as necessary and evaluated them for inclusion.
For the identification of studies considered for inclusion in this
review, we developed detailed search strategies for each database
searched. Please see Appendix 1 for theCENTRAL search strategy,
Appendix 2 for the MEDLINE search strategy, and Appendix 3
for the EMBASE search strategy.
We ran the search for the original version of this review in June
2003, based on the search strategy developed for the Movement
Disorders Group to identify all papers from 1977, the first year
botulinum toxin was used therapeutically in any condition.
Searching other resources
The search strategy also included:
1. searches through reference lists of located trials and review
articles concerning botulinum toxin;
2. handsearch of abstracts of international congresses relevant
in the fields of movement disorders and botulinum toxins, i.e.
American Academy of Neurology, Movement Disorders Society,
International Association of Parkinsonism and Related
Disorders, and International Neurotoxin Association (1985 to
October 2015);
3. personal communication with other researchers in the field;
4. contact with drug manufacturers;
5. whenever necessary, we contacted authors of published
trials for further information and unpublished data.
Data collection and analysis
Selection of studies
Two review authors independently screened the studies identified
by the search strategy, reading each of the titles and abstracts,
excluding studies that were not applicable. If there was no abstract,
we opted to retrieve the full text of the study in question.
Two review authors then independently assessed the full-text arti-
cles to see if the studies fulfilled the inclusion criteria. We resolved
disagreements by discussion or, if necessary, reached consensus
with the participation of a third author.
Data extraction and management
Two authors independently extracted study data onto standardised
forms, after which we cross-checked the forms for accuracy. We
resolved disagreements by discussion or, if necessary, arbitration
by a third author.We extracted the following data from each study.
1. Participants: inclusion and exclusion criteria, demographics
and clinical baseline characteristics, number and reasons for
withdrawals, exclusions and loss to follow-up, if any.
2. Interventions: full description of intervention, duration of
treatment period and follow-up, providers, and co-interventions,
if any.
3. Comparisons: number of randomised participants to each
arm, compliance and dropouts, reasons for dropouts, and ability
to perform an intention-to-treat analysis.
4. Outcomes: definition of outcomes, use of validated
measurement tools, time-point measurements, change from
baseline or post-interventional measures, and missing outcomes,
if any.
5. Study design: interventional, randomised, controlled,
double-blind.
Assessment of risk of bias in included studies
We used the recommended Cochrane tool for assessing risk of
bias in this review (Higgins 2011a). We added one new criteria,
in addition to the seven specific domains of this tool (i.e. random
sequence generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment, incomplete
outcome data, selective reporting and other bias). This extra do-
main, ’enriched population’, was created to evaluate bias origi-
nating from either the preferential enrolment of known positive
responders to BtA (high risk of bias being arbitrarily defined as
>30% of participants being non-naive to Bt) or the exclusion of
known poor responders to BtA.
We also divided the domain ’blinding of outcome assessment’ into
two categories: subjective and objective assessment. Because the
clinical effect of botulinum toxin treatment is easily perceived by
most patients, Bt non-naive patients are likely to recognise the
presence or absence of clinical effects, or frequent adverse events,
or both, effectively revealing the respective allocation arm. Thus,
whenever a study population consisted primarily of non-naive par-
ticipants, we took this potential source of bias for subjective out-
come assessment into account.
Two independent review authors performed critical assessments
for each domain of the risk of bias tool.We resolved disagreements
by discussion and, if necessary, reached consensus with the partic-
ipation of a third author.
Measures of treatment effect
We compared disease symptoms at baseline to disease symptoms
in weeks 3 to 6 between BtB and placebo arms. Whenever possi-
ble, we extracted continuous outcomes. Where we extracted ade-
quate data from the studies, we pooled these data and used them
for comparison. We opted to preferentially use mean differences.
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When studies investigating the same outcome used different val-
idated rating scales, we calculated a standardised mean difference
(SMD). For interpretation of effect sizes with SMDs, we used a
rule of thumb to define absence of effect (SMD < 0.2), a small
effect (SMD = 0.2 to 0.49), a moderate effect (SMD = 0.5 to
0.79), or a large effect (SMD ≥ 0.80) (Cohen 1988). If necessary
for comparison, we dichotomised rating scales using each study
author’s own criteria for improvement or no improvement. If these
criteria were not described, we defined ’improvement’ as any ben-
eficial change from baseline, and ’no improvement’ as lack of im-
provement or any deterioration from baseline.
We compared the proportion of participants with adverse events
between treatment arms using risk ratios, and performed further
analysis for adverse events of special interest reported in the trials.
We planned a meta-analysis for the duration of effect of BtB for-
mulations (using time-to-event data). Where there were no data
that could be combined and subjected to such analysis, we under-
took a narrative approach to result synthesis.
Unit of analysis issues
Studies with multiple treatment groups
Whenever the included studies had multiple BtB arms with dif-
ferent dosages versus placebo, we combined all the BtB groups
to create a single pair-wise comparison, using the Review Man-
ager (RevMan) 5.3 Calculator (RevMan 2014). This avoided the
duplication of the placebo group that would happen if multiple
comparisons (e.g. BtB dose 1 versus placebo; BtB dose 2 versus
placebo) were included in the meta-analysis, as well as the loss
of information if one dosage group was chosen in detriment of
the others. We analysed the importance of dosage in a subgroup
analysis.
Dealing with missing data
Where insufficient data were presented in the study report to com-
bine information into the meta-analysis, we derived the mean
value and standard deviation of the outcome measurements using
the methods suggested in the Cochrane Handbook, Section 16.1
(Higgins 2011b).
We used the generic inverse variance method when an effect esti-
mate and a valid measure of uncertainty (e.g. standard error (SE),
95% confidence interval (CI) or exact P value) were reported in
the study. When two reported groups needed to be combined into
a single group, we calculated a pooled standard deviation (SD) es-
timate (Abrams 2005; Follmann 1992) and used it as the standard
deviation for that group.
When change from baseline SD was not reported or not pos-
sible to extract, we used alternative methods for imputing SD,
namely, those suggested by Cochrane (Cochrane Handbook, Sec-
tion 16.1.3.2). If a study in this review uses the same scale, degree
of error and time period measurements, and SD was available, SD
was appropriated from that study (Higgins 2011b). Where not
possible to use the aforementioned methods, we used a pooled
SD estimate (Abrams 2005; Follmann 1992) instead, assuming a
lower degree of accuracy.
Assessment of heterogeneity
Heterogeneity between trial results was tested using a standard chi-
squared test and an I2 statistic was performed to quantify incon-
sistency across studies (Higgins 2003). When considerable het-
erogeneity was present (i.e. P < 0.1 or I2 > 50%), we explored
the possible causes of heterogeneity by conducting non-planned
subgroup analyses. Where heterogeneity could not readily be ex-
plained by the planned and non-planned exploratory analyses, we
incorporated it into a random-effects (RE) meta-analysis model.
Assessment of reporting biases
We assessed publication bias through visual inspection of funnel
plot asymmetry (Sterne 2001) and Peters’ regression tests (Peters
2006), if more than 10 studies per outcome were available (Sterne
2011).
Data synthesis
We performed statistical analysis with ReviewManager (RevMan)
version 5.3 (RevMan 2014).
We pooled effect measures by applying the Mantel-Haenszel
method for dichotomous outcomes, and applying the inverse-vari-
ance method for continuous and generalised inverse variance out-
comes. We conducted data synthesis using a fixed-effect model
unless considerable heterogeneity was detected, in which case we
opted to apply the random-effects model. We presented all results
with 95% CI.
We calculated the number of participants needed to treat for an ad-
ditional beneficial outcome (NNTB) and for an additional harm-
ful outcome (NNTH) from meta-analysis estimates, rather than
treating data as if they came from a single trial, as the latter ap-
proach is more prone to bias, especially when there are significant
imbalances between groups within one or more trials in the meta-
analysis (Altman 2002). However, caution is needed in interpret-
ing these findings since they may be misleading because of vari-
ation in the event rates in each trial, differences in the outcomes
considered, effects of secular trends on disease risk, and differences
in clinical setting (Smeeth 1999).
Where data from the study reports could not be combined into a
meta-analysis, we presented a narrative report of result synthesis
in the review text.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analysis for the following areas, indepen-
dently of the presence or not of significant heterogeneity: high (≥
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10000 U) versus medium (> 2500 U to < 10000 U) versus low
total treatment dose (≤ 2500 U), all defined arbitrarily; EMG-
guided versus non-EMG- guided injection; and BtA-responsive
versus BtA-non-responsive
R E S U L T S
Description of studies
We included one new study in this update (Kaji 2013, n = 130),
adding to the three studies already included in the original review
(Brashear 1999; Brin 1999; Lew 1997).
Overall, we included four parallel-designed studies comparingBtB
(different total treatment doses) with placebo in this update, with
a total of 441 participants with cervical dystonia.
Results of the search
The search, last run on 26 October 2015, returned 1667 records
(189 throughCENTRAL, 436 thoughMEDLINE, 1042 through
EMBASE), resulting in 1450 records after removing all duplicates.
After title and abstract screening we retrieved twelve full articles.
Of these, we excluded a further eight studies, one due to examin-
ing the wrong intervention (AN072-008 1995) and seven due to
having the wrong study design (Chinnapongse 2010; Cullis 2000;
Dressler 2005; Jacob 2003; Jankovic 2006; Lew 2002; Truong
1997). We did not retrieve any unpublished trials.
We once again included the three studies that had been included
in previous versions of this review (Brashear 1999; Brin 1999; Lew
1997) and we included one new study in both the qualitative and
quantitative syntheses (Kaji 2013).
See Figure 1 for the Study flow diagram.
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Figure 1. Study flow diagram
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Included studies
We have listed all the included studies in this review in the
’Characteristics of included studies’ table.
Study participants
The four included studies enrolled a total of 441 adult (aged above
18 years old) participants (57.6% of whomwere female (n = 254)).
The mean age was 52.9 years across all studies except Lew 1997,
where age distribution was not available. Trial size varied from 77
to 133 participants, with all but one study (Brin 1999) enrolling
above 100 participants. Three of the included RCTs were multi-
centre studies conducted in theUS and published in the late 1990s
(Brashear 1999; Brin 1999; Lew 1997), and one was a more recent
trial conducted in Japan (Kaji 2013). All trials tested only one
injection treatment session and followed participants for 16weeks.
With respect to baseline characteristics, all studies required par-
ticipants to have had cervical dystonia for at least one year. The
mean duration of cervical dystonia was 7.21 years in the Kaji 2013
trial (ranging from 5.58 years in the 5000 U BtB treatment arm
to 8.53 years in the 2500 U BtB treatment arm); the remaining
studies did not present the mean duration of disease in the popu-
lation enrolled. The baseline mean cervical dystonia impairment
was moderate to severe in all participants, though well matched
between study arms, with TWSTRS total scores ranging from43.4
to 52.0, and TWSTRS Severity scores from 19.6 to 22.4 (baseline
scores not available in Lew 1997, and sub-scores not reported in
Kaji 2013).
Participants’ previous Bt response varied across trials. Lew 1997
and Kaji 2013 trials allowed both BtA-responsive and BtA-non-
responsive participants to enter the study; the Brin 1999 trial al-
lowed only BtA-non-responders; and the Brashear 1999 trial in-
cluded only BtA-responsive participants. Only the Kaji 2013 trial
enrolled BtA-naïve participants (25.4% of total population); in
all studies, time since last injection before study entry had to be
superior to 16 weeks. All trials except Kaji 2013 excluded clinical
forms of cervical dystonia known to perform poorly to botulinum
toxin injections, such as pure anterocollis or retrocollis.
The number of withdrawals was small and balanced in all trials.
Reasons for withdrawals were given, even though Kaji 2013 did
not describe the reasons for each participant withdrawal in detail.
Overall, within studies, participants were well matched between
BtB and placebo arms.
Study design and interventions
All studies were designed to evaluate only a single treatment ses-
sion. Total BtB dosages tested varied between studies. All trials
assessed the effect of 10,000 U of BtB (a dose that we have ar-
bitrarily classified as being a high dose). Three studies (Brashear
1999; Kaji 2013; Lew 1997) also included a group treated with
5000 U of BtB (a dose that we have arbitrarily classified as being
a medium dose), and two studies (Kaji 2013; Lew 1997) further
included a group treated with 2500 U (a dose that we have arbi-
trarily classified as being a low dose).
Techniques and schema of BtB administration did not vary con-
siderably among the studies. In all the trials, BtB was injected into
two to four involved cervical dystonia muscles selected by the in-
vestigator, with the use of electromyography left at the discretion
of the investigator performing the injection.
All trials were short-term, with an observational period lasting 16
weeks post-injection. No re-injections were allowed.
Three studies (Brashear 1999; Brin 1999; Kaji 2013) assessed ef-
ficacy and other primary outcomes using an intent-to-treat (ITT)
analysis, which included all participants randomised to treatment
or, in the case of Kaji 2013, all those to whom treatment was ad-
ministered. Lew 1997 assessed efficacy and safety outcomes on the
per-protocol (PP) population; this study also used an ITT analysis
to assess the duration of effect.
Excluded studies
We have listed all the excluded studies in this review, together
with reasons for their exclusion, in the ’Characteristics of excluded
studies’ table.
One study had been excluded from the original analysis since it
was not fully published and relevant data was lacking (AN072-008
1995). It was a dose-finding parallel-designed study comparing a
single treatment session of BtB in three different doses (400 U,
1200 U, 2400 U) against placebo, doses currently thought to be
insufficient for the great majority of CD patients. The follow-up
period was 16 weeks. Both BtA-responsive and non-responsive
participantswere enrolled, and the primary outcomewas change in
TWSTRS total score. All three experimental groups had large rates
of withdrawals (400 U: 71%, 1200 U: 73%, 2400 U: 48%). For
all but two of the participants, who hadwithdrawn from the study,
the reason was the protocol-defined criteria, ‘lack of response’. We
asked the drug company for further information, without success.
Our research did not find any additional publications on this trial
that could shed any light on this problem, and because we could
not rule out selective reporting of results, we decided that this
study should remain excluded from our review. Two other par-
allel-designed studies comparing different doses of BtB had been
excluded from the original review (Cullis 2000; Truong 1997) for
lacking a placebo group.
From the updated searches, we excluded a further five studies as one
was neither blindednor placebo-controlled (Chinnapongse 2010);
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one was not placebo-controlled (Jacob 2003); one was a post-hoc
analysis of two trials already included in this review (Lew 2002),
and two were non-randomised, non-controlled studies focusing
on the immunogenicity of BtB (Dressler 2005; Jankovic 2006).
Risk of bias in included studies
The quality assessment of previously included studies was re-eval-
uated with the Cochrane Risk of bias tool (current at the time of
writing), the results of which can be found in Figure 2 and Figure
3. These assessments were based on the information available in
the primary report data.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Overall, no studies were considered to be at low risk of bias across
all domains. High risk of bias was attributed only to “enriched
population” and “other bias” domains.
Allocation
Two studies (Brashear 1999; Brin 1999) described the process of
random sequence generation, in both controlled by an indepen-
dent organisation; we assessed the other two studies to be at un-
clear risk of bias for this criterion.
Three studies (Brashear 1999: Brin 1999; Kaji 2013) described an
adequate allocation concealment process and were rated as being
at a low risk of bias, whereas we assessed the remaining study as
being at unclear risk of bias.
Blinding
We evaluated the risk of bias in blinding of participants and per-
sonnel involved in the trial to be low for all the studies included in
this review, since all trials were described as being double-blinded
and all used vials with identical appearance to mask the interven-
tion employed.
We considered two studies to have adequately blinded investigators
measuring objective outcomes (Brashear 1999; Brin 1999); the
other two studies did not provide sufficient information to permit
judgement, so we rated them as having an unclear risk of bias.
For the assessment of subjective outcomes, we considered all stud-
ies to have an unclear risk of bias: Kaji 2013 did not specify the
blinding process, and all the other studies enrolled only partici-
pants who had previously been treated with botulinum toxin. We
considered that studies including only non-naive participants may
introduce bias in patient-reported assessment of subjective out-
comes.
Incomplete outcome data
In Lew 1997, all participants completed the study per protocol.
In the remainder, missing outcome data was balanced in numbers
across intervention groups and adequate imputationmethodswere
used (ITT). Reasons for missing data were unclear only in Kaji
2013, but we considered the reasons for participant attrition to be
unlikely to motivate output imbalances.
Selective reporting
Themore clinically relevant outcomes, which are usually evaluated
in intervention trials for this condition,were reported in all studies,
so we considered them to be at low risk of bias for reporting data.
No trial protocol registry was available for any of the four included
studies. However, three of these studies were conducted in the
1990’s, before trial registration became standard good practice for
clinical investigations.
Other potential sources of bias
Enriched population
Brashear 1999 exclusively enrolled BtA-responsive participants,
and was classified as having a high risk of bias for enriched pop-
ulation. All the other studies allowed BtA-non-responsive partici-
pants.
On the other hand, three studies (Brashear 1999; Brin 1999; Lew
1997) excluded forms of cervical dystonia known to have a poorer
clinical response to BtA injection, and were considered to be at a
high risk of bias for this domain.
Other Bias
Two trials (Brashear 1999; Brin 1999) declared funding or supply
of study vials from industry sources, being rated at a high risk of
bias for funding and potential conflicts of interest. Kaji 2013 did
not provide a description of funding, but members of a pharma-
ceutical company were authors of the study, so this trial was also
classified as high risk of bias for this domain. Lew 1997 was clas-
sified at unclear risk of bias for not stating the source of funding.
Publication bias
We intended to use funnel plots to explore publication bias. How-
ever, due to the small number of included studies, the power of
this analysis was considered to be inadequate (Sterne 2011).
Effects of interventions
See: Summary of findings for the main comparison Botulinum
neurotoxin B compared to placebo for cervical dystonia
The key results of this review can be found in ’Summary of findings
for the main comparison’.
Botulinum toxin type B versus placebo
Preceding data analysis
Whenever necessary, we used appropriate imputation methods in
order to combine the reported data into the meta-analysis with
other studies for which full data were available (see Dealing with
missing data). Brashear 1999 and Brin 1999 reported the primary
outcome (mean and SD) as total scores for the time point assessed;
we obtained change from baseline SD values using pooled SD
estimates.
All studies evaluating different BtB dosages (Brashear 1999; Kaji
2013; Lew1997) presented data separately for each dose, reporting
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sample sizes, means and SD (when available) for each intervention
group. When an overall dose was required to compare to other
studies, we combined the reported subgroups using RevMan 5.3
(seeUnit of analysis issues) (RevMan 2014).We used the same tool
to calculate SD values from SE values presented in Kaji 2013. We
conducted sensitivity analyses for every study where imputation
methods were applied.
Primary outcomes
1. Overall improvement on any validated symptomatic rating
scale for cervical dystonia
The primary outcome in all trials included in this review was
change in Toronto Western Spasmodic Torticollis Rating Scale
(TWSTRS) (Consky 1994) total or subtotal scores, assessed at
week 4 following initial injection of BtB. TWSTRS is currently the
most common clinical validated tool to assess and document the
status of patients with spasmodic torticollis. The TWSTRS (total
score range, 0 to 85) is composite of three sub-scales that evaluate
different features of CD, namely severity (range, 0 to 35), disability
(range, 0 to 30) and pain (range, 0 to 20). The higher the score,
the greater the level of morbidity. In the absence of a validated
value for a clinically meaningful change in TWSTRS total score,
we have considered a 10% change from patients’ baseline status as
a clinically meaningful change.
Three trials (Brashear 1999; Brin 1999; Kaji 2013) reported data
as themean change from baseline in the TWSTRS total-score, and
demonstrated an improvement in participants treated with BtB
compared to placebo mean difference (MD) 6.78; 95% CI 4.54
to 9.01; I2= 0%) (Analysis 1.1). This represents an improvement
of 14.7% from the participant’s baseline clinical status (46.3 TW-
STRS combined score). Lew 1997was not included in this primary
analysis because SD values were not reported. As the study pop-
ulation was not described in detail, lacking important data such
as age distribution, duration and severity of disease, we could not
impute SD values from similar studies with an acceptable margin
of error. However, data from this trial was used to assess NNTB.
The NNTB in TWSTRS total score was three patients (95% CI
2 to 6).
With respect to TWSTRS sub-scores, BtB was associated with a
mean reduction of 2.43 points in TWSTRS Severity (95% CI
1.24 to 3.63; I2= 0%), and of 2.29 points in TWSTRS Disability
(95%CI 1.04 to 3.54; I2= 0%). Brashear 1999 was not included in
this analysis of TWSTRS sub-scales as it did not present objective
efficacy data for all groups.
1.1. Overall improvement with low vs medium vs high dose of
BtB
We carried out a subgroup analysis to assess overall improvement
according to BtB dose (see Subgroup analysis and investigation of
heterogeneity). All trials tested high BtB dose (10,000 U); three
tested medium BtB dose (5000 U), and two tested low BtB dose
(2500 U).
All BtBdoseswere efficacious against placebo (low-dose:MD6.95;
95% CI 3.70 to 10.21; I2= 0%; medium-dose: MD 6.10; 95%
CI 3.40 to 8.81; I2= 0%; high-dose: MD 8.72; 95% CI 6.35 to
11.10; I2= 0%). There was no difference in overall improvement,
as assessed with TWSTRS global score, between these dose-de-
fined subgroups (P= 0.34; I2 = 6.9%) (Analysis 1.2).
1.2 Overall improvement with non-EMG guided vs EMG-
guided injections
In all trials, the use of EMG-guidance was left at the discretion
of the investigator. No data were reported concerning participants
that did or did not undergo EMG-guided injection. Thus, it was
not possible to perform this planned subgroup analysis.
1.3 Overall improvement in BtA-responsive vs BtA-non-
responsive participants
Two trials (Kaji 2013; Lew 1997) enrolled both types of patients.
However, we did not include these studies in this analysis because
they did not present mean TWSTRS values for each subgroup.
Brashear 1999 included only BtA-responsive participants, and
Brin 1999 included only BtA-non-responsive participants. Over-
all, BtA-responsive participants improved by 6.22 points (95%CI
1.83 to 10.60), while BtA-non-responsive participants improved
by 9.0 points in TWSTRS total score (95% CI 4.46 to 13.54).
This difference (2.78 points on the TWSTRS total score) between
BtA-responsive and BtA-non-responsiveparticipants was not sig-
nificant (P = 0.39; I2= 0%) (Analysis 1.3).
Lew 1997, which included both types of participants, reported a
higher rate of participants classified as ’responders’ among partic-
ipants who were non-responsive to BtA in comparison to partici-
pants who were responsive to BtA (25% versus 66.7% ).
2. Number of participants with any adverse event
2.1 Proportion of participants with adverse events
Adverse events were generally transient and either mild to moder-
ate, or intermittent. They were reported by 90.2% of the partici-
pants in the BtB groups, compared to 83.8% of participants in the
placebo arm (RR 1.09; 95% CI 0.97 to 1.23; I2= 45%) (Analysis
1.4). This analysis included only two studies (Brashear 1999; Brin
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1999) as the others (Kaji 2013; Lew 1997) did not present the
total number of participants with adverse events per group.
2.1.1 Proportion of participants with adverse events with low
vs medium vs high dose of BtB
Brashear 1999 and Brin 1999 were the studies included for this
subgroup analysis. We excluded Kaji 2013 and Lew 1997 because
they did not provide data according to the BtB dosages used.
There was no difference in the overall risk of any adverse event
between medium (RR 1.07; 95% CI 0.89 to 1.29) or high-dose
(RR1.09; 95%CI 0.89 to 1.33; I2= 59%)BtB-treated participants
and placebo (Analysis 1.5).
2.1.2 Proportion of participants with adverse events in BtA-
responsive vs BtA-non-responsive participants
The overall risk of adverse events reported by Brashear 1999 (with
exclusively BtA-responsive participants) was similar between the
BtB and placebo groups (RR 0.97; 95%CI 0.79 to 1.20) (Analysis
1.6). The overall risk of adverse events reported by Brin 1999
(with exclusively BtA-non-responsive participants) was higher in
the BtB group (RR 1.19; 95% CI 1.03 to 1.37).
Secondary outcomes
1. Change in subjective evaluation of clinical status evaluated
by both participants and clinicians
Subjective evaluation of overall improvement by both participants
and clinicians was assessed in all trials at week 4 after BtB injection.
The trials used two scales to quantify overall improvement: the
Global Assessment of Change (GAC) and the Visual Analogue
Scale (VAS). GAC ranges from “Very marked worsening” (- 4) to
“Complete resolution of CD symptoms” (+ 4). VAS (range, 0 mm
to 100 mm) assesses the change from baseline in symptom severity,
where 0 mm indicates “Much worse”, 50 mm: “No change”, and
100 mm: “Symptom-free”.
Two of the trials included in quantitative synthesis (Brashear 1999;
Brin 1999) reported this outcome using mean change from base-
line on the GAC scale whilst the other study (Kaji 2013) reported
this outcome as the mean change from baseline on the on the VAS
scale, with both dimensions of the outcome (participant and clini-
cian assessments) being reported in all three studies. Overall, both
participants and clinicians reported an improvement of subjective
clinical status, with a SMDof 0.86 (95%CI 0.61 to 1.10; I2= 0%)
(Analysis 1.7) and 0.80 (95% CI 0.55 to 1.04; I2= 0%) (Analysis
1.8) , respectively.
Lew 1997 reported that there was a significant (P = 0.0001) im-
provement among BtB-treated participants in both Patient and
Investigator Global Assessment ratings. However, since these data
were not fully reported, we could not include this trial in themeta-
analysis for this outcome.
All three trials (Brashear 1999; Brin 1999; Kaji 2013) reporting
extractable data for subjective assessments were meta-analysed ac-
cording to the doses of BtB used, and all doses were associated with
a significant benefit when compared to placebo in both participant
and clinician subjective assessments (Analysis 1.9 and Analysis
1.10, respectively). There were no differences between the differ-
ent dose-based subgroups (low versus medium, versus high-dose
BtB).
Two trials (Brashear 1999; Brin 1999) reported subjective assess-
ment data with regards to BtA-responsive and BtA-non-responsive
participants. These data were meta-analysed, though we found no
differences between the different BtA-responsiveness subgroups
(see Analysis 1.11 and Analysis 1.12).
2. Changes in pain scores, as assessed with validated
assessment tools
Two trials (Brin 1999; Kaji 2013) provided data on TWSTRS
pain sub-scores (range, 0 to 20), and reported an improvement in
participants treated with BtB compared to placebo with a MD of
2.20 (95% CI 1.25 to 3.15; I2= 58%) (Analysis 1.13). We did not
include Lew 1997 in thismeta-analysis because they did not report
SD values for the overall intervention group, although they did
report SD values for dose subgroups. As they did not describe the
study population in sufficient detail, lacking important data such
as age distribution, duration and severity of disease, we decided
not to impute SD values from similar studies as the margin of
error would be unknown. Brashear 1999 did not report data for
this outcome.
We meta-analysed three trials (Brin 1999; Kaji 2013; Lew 1997)
that reported data as mean change from baseline on the TWSTRS
pain sub-scale, according to the doses of BtB used. These trials
were associated with significant benefit when compared to placebo
(Analysis 1.14). However, we found no differences between the
different dose-based subgroups (low versus medium, versus high-
dose BtB).
Two trials (Brashear 1999; Brin 1999) reported pain relief data
with regards to BtA-responsive and BtA-non-responsive partici-
pants. Subgroup analysis did not identify any differences between
the different BtA-responsiveness subgroups (see Analysis 1.15).
3. Changes in quality of life assessments
Lew 1997 assessed quality of life with the Sickness Impact Profile
(SIP), a 136-item questionnaire evaluating quotidian activities, di-
vided into 12 categories: emotional behaviour, social interaction,
alertness behaviour, communication, body care and movement,
ambulation, mobility, sleep and rest, home management, work,
recreation and pastimes, and eating. The results are given in per-
centages, highest scores representing more disabling status. This
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trial did not report definitive data , although it does state that
scores in the BtB arm did not differ significantly from those in
the placebo arm. None of the other studies (Brashear 1999; Brin
1999; Kaji 2013) reported data on this outcome.
4. Number of withdrawals due to adverse events, including
adverse events caused by the intervention (type A or type B,
or both, adverse drug reactions (ADRs)), and failure of
therapy (type F ADRs)
All the included trials reported the number of withdrawals due
to adverse events without differences between BtB and placebo
(RR 0.88; 95% CI: 0.19 to 4.06; I2= 0%) (Analysis 1.20). For the
purpose of this analysis we considered that adverse events may be
caused by the intervention (i.e. type A and/or type B ADRs), or
lack of efficacy of the treatment (i.e., failure of therapy, a type F
ADRs) (Edwards 2000).
The most frequent reason for withdrawal due to adverse events
was failure of therapy, which was reported in two participants in
Brashear 1999 (one in the BtB arm and the other in the placebo
arm) and in two BtB-treated participants in the Kaji 2013 trial.
Withdrawals due to adverse events occurred in one participant in
the placebo arm in Brin 1999 and in one BtB-allocated participant
in Brashear 1999. The former participant experienced neck pain,
headache, urticaria, eye pain, asthenia and nausea, and the latter
died after triple-vessel coronary artery bypass surgery performed
on study day 67, considered unrelated to CD treatment.
5. Number of participants with adverse events of special
interest
The most frequent adverse events reported were dry mouth (RR
7.65; 95% CI 2.75 to 21.32; I2= 0%) and dysphagia (RR 6.78;
95%CI 2.42 to 19.05; I2= 0%), which occurred in 17% of partic-
ipants in the BtB group versus 3% in the placebo group (Analysis
1.21, Analysis 1.22). The NNTH for dry mouth and dysphagia
was 7 (95% CI 26 to 2) and 8 (95% CI 32 to 3), respectively.
For all the other adverse events no significant differences were
found. Nevertheless, the following adverse events were more fre-
quent with BtB than placebo: injection site pain (RR 1.39; 95%
CI 0.73 to 2.66; I2= 0%), nausea (RR 2.06; 95% CI 0.68 to 6.28;
I2= 0%), headache (RR 1.90; 95% CI 0.82 to 4.41; I2= 0%), pain
(RR 1.15; 95% CI 0.51 to 2.62; I2= 0%), infection (RR 1.14;
95% CI 0.38 to 3.38; I2= 61%) and flu syndrome (RR 1.44; 95%
CI 0.23 to 8.92; I2= 67%).
We performed subgroup analysis according to BtB dose for the
two most common adverse events, dry mouth and dysphagia. In
comparison to placebo, dry mouth was significantly higher among
high-dose BtB-treated participants (RR 11.47; 95% CI 3.95 to
33.30; I2= 0%), but not amongmedium and low-dose BtB-treated
participants in comparison to placebo. However, overall risk of dry
mouth was no different between the dose-defined subgroups (P
= 0.18; I2= 41%) (Analysis 1.23). The risk of dysphagia was sig-
nificantly higher among high- (RR 9.19; 95% CI 3.38 to 25.01;
I2= 0%) and medium-dose (RR 5.50; 95% CI 1.25 to 24.17; I
2= 0%) BtB-treated participants, but not among low-dose BtB-
treated participants in comparison to placebo. However, overall
risk of dysphagia was no different between the dose-defined sub-
groups (P = 0.85; I2= 0%) (Analysis 1.24).
It is noteworthy that all above mentioned adverse events occurred
in more than 10% of BtB-treated participants.
6. Duration of effect, or number of days until need for
reinjection or effect waning
Three trials (Brashear 1999; Brin 1999; Lew 1997) assessed du-
ration of clinical benefit, defined as the time until return to base-
line TWSTRS total score. In all trials, the duration of effect thus
defined was between 12 and 16 weeks. Data suggested that the
change inTWSTRS total score over timewas somewhat shorter for
the lower doses (2500-5000 U) than for the higher dose (10,000
U). Since the studies performed only one treatment session, no
data was available for long-term duration of benefit. The newly
included study (Kaji 2013) did not assess duration of effect. We
did not conduct meta-analysis due to lack of combinable data
(Michiels 2005).
D I S C U S S I O N
Summary of main results
This updated review included four randomised, parallel-designed,
placebo-controlled trials, enrolling 441 participants with cervical
dystonia, of whom 92.5% had been previously treated with BtA.
In comparison to placebo, BtB was effective in reducing overall
disease impairment, including disease severity, disability and as-
sociated pain. An improvement of 14.7% from the participant’s
baseline clinical status was found among participants treated with
BtB four weeks after a single treatment cycle, reducing by nearly
7 points in TWSTRS-total score and yielding an NNTB of 3
(for any improvement in TWSTRS-total score). Subjective assess-
ments by both participants and clinicians also favoured BtB in
comparison to placebo. The impact of BtB on other domains of
participants’ quality of life, such as social functioning or mental
health, have not properly been addressed in the included trials.
Overall, there was no difference in rates of adverse events and
withdrawals due to adverse events between groups. However, the
short duration of the trials, as well as the reduced sample size,
precludes strong conclusions with regards to the lack of differ-
ences between BtB and placebo. Themost common adverse events
that were different between the BtB and placebo groups were dry
mouth and dysphagia, both considered related to treatment and
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being about six times more frequent among BtB-treated patients,
with an NNTH of 7 and 8, respectively. No fatalities or serious
adverse events were considered related to BtB treatment in any of
the trials. Data for special subpopulations, such as children and
pregnant women, were not available.
BtB doses
All dosages were efficacious against placebo, but we found no clear-
cut evidence of a dose-response gradient. It is however notewor-
thy that these trials were not dose-response studies and that this
conclusion was based on arbitrarily defined dose-subgroup analy-
ses. On the other hand, higher BtB dosages were associated with
a higher risk of dysphagia and dry mouth.
BtA-responsive versus BtA-non-responsive participants
The percentage improvement of disease impairment reported in
one trial enrolling exclusively BtA-non-responders was higher than
that reported in another trial enrolling exclusively BtA-respon-
ders. The reduced sample size precludes strong conclusions with
regards to these results, which could be due to several confound-
ing factors, such asmethodological differences and population im-
balances between the two trials. One further trial, enrolling both
types of participants, also suggested a higher efficacy among BtA-
non-responders. As for adverse events, we found no differences
between the groups.
Duration of effect
The effect of BtB lasted approximately 12 to 16 weeks, as assessed
by the time needed to return to baseline TWSTRS total scores.
Duration of effect thus defined was greater in the subgroup of
participants treated with higher BtB doses. Long-term duration
of effect could not be evaluated as all trials evaluated only a single
treatment session.
Overall completeness and applicability of
evidence
All included trials addressed the primary outcome of our review
using the same assessment tool.However, some did not fully report
all outcome data, and in some cases results could not be pooled and
compared across studies. This limits the amount of data available
and, consequently, the confidence in overall conclusions.
Four noteworthy factors challenge the implementation of the evi-
dence in this review. First, there was a limited and considerably het-
erogeneous regional distribution, with one trial being conducted
in Japan and three in the United States. Differences in clinical
practice, training of experts, and local guidelines in other regions
of the world may present an obstacle to the application of the
evidence here demonstrated. Second, sample size across included
trials was relatively small and many subgroup analyses for the out-
comes of interest present only trends in the results. More studies
are needed to provide robust evidence for these trends. Third, the
enrolment of enriched populations in clinical trials limits applica-
bility of results into clinical practice, as complex and potentially
poorer responders are usually excluded in these trials. The fact
that these patients are common in clinical practice further com-
plicates issues of generalisation. Fourth, patients frequently have
concomitant medications for their condition, such as muscle re-
laxants and benzodiazepines. In trials, such medications are rea-
sonably required to be on a stable dose for many weeks to avoid
confounding factors. As a result, little is currently known about
the impact of these drug regimens with regards to implementation
of the evidence in this review.
Quality of the evidence
See Characteristics of included studies, ’Risk of bias’ tables and
’Risk of bias’ summary tables (Figure 2; Figure 3).
Only two of the included studies adequately described their ran-
domisation and allocation methods, with the remaining two trials
being assessed at an unclear risk of bias for these items. All studies
were considered appropriately blinded in general; however, only
two provided satisfactory descriptions of blinding of objective out-
come assessment, and all were considered possibly biased regard-
ing subjective outcome assessment, as all studies predominantly
enrolled patients with previous treatment with BtA. This repre-
sents major methodological limitations that may have resulted in
a biased assessment of the intervention effect, particularly with
regards to subjective outcomes, which are highly susceptible to bi-
ased estimations, namely pain assessment, subjective assessment by
participants and clinicians, and quality of life assessments. Finally,
statistical heterogeneity was present for pain and adverse events
outcomes which could not be clearly explained by the subgroup
analysis performed. However, results from individual studies were
all in the same direction.
Some outcomes could not be compared across studies, as some
studies lacked reporting of relevant data. Imbalances between base-
line characteristics of the participants and incomplete description
of the variables meant that we could not confidently impute values
for missing data, further reducing the amount of combinable data,
and therefore the precision of the results.
The included trials enrolled between 77 and 133 participants, and
although individually these trials were underpowered, the pooling
of the trials permitted an adequate sample size for the majority
of efficacy outcomes. Taken together, we consider that there is
moderate quality evidence that a single treatment session of BtB, in
certain types of cervical dystonia, is efficacious in reducing disease
impairment, including severity, pain and disability. However, the
quality of the evidence is low and no robust conclusions can be
made regarding safety and tolerability, including withdrawals due
to adverse events, as well as regarding continued responsiveness
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and long-term efficacy, which are important aspects in a chronic
condition such as cervical dystonia.
Potential biases in the review process
Although we followed the methods recommended by Cochrane
in order to minimise bias in the review process, certain areas are
deserving of attention on the part of readers. Despite having con-
tacted experts in the area, not having searched clinical trial reg-
istries opens the current review to two potential problems: firstly,
possibly havingmissed trials and also the possibility of introducing
publication bias.
The newly added trial was published in Japanese only. Results
tables were presented in English, and important information was
extracted from the text by a Japanese collaborator (Dr. Masao
Kaneshige). Even though we took steps to minimise this potential
source of bias, we cannot ignore its existence.
Agreements and disagreements with other
studies or reviews
Overall, the results of this updated review are in agreementwith the
conclusions of earlier versions. However, we now conclude that no
claims can be made regarding a clear-cut dose-response relation-
ship for efficacy outcomes. On the other hand, a clear dose-depen-
dent relationship exists for the treatment-related adverse events of
special interest, such as dysphagia and dry mouth.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A single treatment session of BtB is effective and well-tolerated
in the treatment of both BtA-non-reponsive and BtA-responsive
adults with certain types of cervical dystonia. No conclusions can
be made regarding people with pure retrocollis or anterocollis
as these were predominantly excluded in the clinical trials. Dry
mouth and dysphagia are the most frequent treatment-related ad-
verse events, although they were not associated with treatment dis-
continuation.
Higher doses of BtB are associated with a higher risk of most
frequent adverse events, without a clear dose-benefit response. No
conclusions canbemade frompublisheddata aboutwhether EMG
guidance of BtB injections improves efficacy or safety outcomes.
Implications for research
The qualitative net benefit of a single BtB injection in the treat-
ment of cervical dystonia has been established in published trials.
Nonetheless, further studies are needed to establish the relative ef-
fectiveness of different doses of BtB, assessing efficacy, safety, du-
ration of effect and quality of life across regimes. Because therapy
typically requires optimising a dose for each patient rather than
administering fixed units of botulinum toxin, such a line of re-
searchwould be important to support the physician’s management
of doses and allow for a more solid and safe individualisation of a
patient’s treatment.
New trials should also assess the potential added benefit of EMG-
guided botulinum toxin treatments. This would also help to clarify
the clinical advantage of training experts in using such techniques.
Trial authors should endeavour to fully study and report data on
BtA-responsive and BtA-non-responsive participants. Consider-
ing that a large number of peoplewho are treatedwithBtB are BtA-
non-responsive, it would be clinically useful to directly compare
BtB effectiveness between BtA-non-reponsive and BtA-responsive
patients. At the moment there is insufficient evidence to support
the claim that a higher benefit due to BtB can be elicited from
either group.
Future research concerning all formulations of botulinum toxin
should endeavour to establish clinical effectiveness not only based
on changes from baseline, but preferably based on validated mea-
sures ofMinimal Clinically ImportantDifference/Change (Brozek
2006). Research is required in order to establish such a parameter
for the TWSTRS, currently the most widely used and dissemi-
nated clinical scale in the field. We are, however, aware of an effort
to create a new clinical scale in dystonia - the Comprehensive Cer-
vical Dystonia Rating Scale (Comella 2015), which will include a
revision of the TWSTRS, to be named TWSTRS-2, with a Min-
imal Clinically Important Change validation being planned.
It is currently uncertain whether or not the clinical effectiveness
of botulinum toxin decays over time, with repeated treatment ses-
sions, or whether a possible loss of effectiveness occurs in all clin-
ical domains. Another related aspect is the possible development
of BtB-non-responsiveness. Future research should address these
important prognostic aspects.
Finally, in conducting this systematic review we were faced with
the fact that there is no defined Core Outcome Set in cervical
dystonia research, as there is in other areas (Tugwell 2007). The
definition of a set of core outcome measures to be included in
future research, via well-establishedmethodology to determine the
inclusion of patient-reported outcomes (Macefield 2014) would
be relevant to promote research in this field, as well as to support
the clinical effectiveness of BtB.
A C K N OW L E D G E M E N T S
We would like to sincerely thank Ema Roque (Cochrane Move-
ment Disorders), Daisy Abreu (Clinical Pharmacology Unit, Fac-
21Botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ulty of Medicine of Lisbon), Francesca Fiorentino (CEMBE),
Nate J. Kosher (American Academy of Neurology) and Masao
Kaneshige (Department of Clinical Neuroscience, Tokushima
University Graduate School) for their contribution to this review.
R E F E R E N C E S
References to studies included in this review
Brashear 1999 {published data only}
Brashear A, Lew MF, Dykstra DD, Comella CL, Factor
SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc
(Botulinum toxin type B) in type A-responsive cervical
dystonia. Neurology 1999;52 (Suppl 2):A292 (S46.003).
∗ Brashear A, Lew MF, Dykstra DD, Comella CL, Factor
SA, Rodnitzky RL, et al. Safety and efficacy of NeuroBloc
(Botulinum toxin type B) in type A-responsive cervical
dystonia. Neurology 1999;53(7):1439–46.
Factor S. Safety and efficacy of Neurobloc (Botulinum toxin
type-B) in type-A responsive and type-A resistant patients
with cervical dystonia. Toxins’99 (www.wemove.org).
1999:9.
Factor S, Adler CH, Brashear A, Brin MF, Comella CL,
Dykstra DD, et al. Safety and efficacy of Neurobloc
(Botulinum toxin type-B) in type-A responsive and type-A
resistant patients with cervical dystonia. Movement Disorders
2000;15 (Suppl 2):7.
Koller M, Wallace JD, Willmer-Hulme A, Chiang P,
Murray JJ. Evaluation of Neurobloc (Botulinum toxin type
B) efficacy in patients with cervical dystonia. Movement
Disorders 2000;15 (Suppl 2):31.
Lew MF, Brashear A, Factor S. The safety and efficacy of
Botulinum toxin type B in the treatment of patients with
cervical dystonia: summary of three controlled clinical
trials. Neurology 2000;55 (Suppl 5):S29–S35.
Brin 1999 {published data only}
∗ Brin MF, Lew MF, Adler CH, Comella CL, Factor
SA, Jankovic J, et al. Safety and efficacy of NeuroBloc
(Botulinum toxin type B) in type A-resistant cervical
dystonia. Neurology 1999;22;53(7):1431–8.
Brin MF, Lew MF, Adler CH, Comella CL, Factor SA,
Jankovic J, et al. Safety and efficacy of NeuroBloc
(Botulinum toxin type B) in type A-resistant cervical
dystonia. Neurology 1999;52 (Suppl 2):A293 (S46.004).
Factor S. Safety and efficacy of Neurobloc (Botulinum toxin
type-B) in type-A responsive and type-A resistant patients
with cervical dystonia. Neurology 1999;7:1431–8.
Factor S, Adler CH, Brashear A, Brin MF, Comella CL,
Dykstra DD, et al. Safety and efficacy of Neurobloc
(Botulinum toxin type-B) in type-A responsive and type-A
resistant patients with cervical dystonia. Movement Disorders
2000;15 (Suppl 2):7.
Koller M, Wallace JD, Willmer-Hulme A, Chiang P,
Murray JJ. Evaluation of Neurobloc (Botulinum toxin type
B) efficacy in patients With cervical dystonia. Movement
Disorders. 2000; Vol. 15 (Suppl 2):31.
Lew MF, Brashear A, Factor S. The safety and efficacy of
botulinum toxin type B in the treatment of patients with
cervical dystonia: summary of three controlled clinical
trials. Neurology 2000;55 (Suppl 5):S29–S35.
Kaji 2013 {published data only}
Kaji R, Shimizu H, Takase T, Osawa M, Yanagisawa N. A
double-blind comparative study to evaluate the efficacy and
safety of NerBloc (rimabotulinumtoxinB) administered in
a single dose to patients with cervical dystonia. Brain and
Nerve 2013;65(2):203–11.
Lew 1997 {published data only}
Koller M, Wallace JD, Willmer-Hulme A, Chiang P,
Murray JJ. Evaluation of Neurobloc (Botulinum toxin type
B) efficacy in patients with cervical dystonia. Movement
Disorders 2000;15 (Suppl 2):31.
∗ Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor
SA, Massey JM, et al. Botulinum toxin type B: a double-
blind, placebo controlled, safety and efficacy study in
cervical dystonia. Neurology 1997;49:701–7.
Lew MF, Brashear A, Factor S. The safety and efficacy of
Botulinum toxin type B in the treatment of patients with
cervical dystonia: summary of three controlled clinical
trials. Neurology 2000;55 (Suppl 5):S29–S35.
References to studies excluded from this review
AN072-008 1995 {published data only}
American BotB Cervical Dystonia Study Group. BotB
(Botulinum toxin type B) in the treatment of cervical
dystonia (CD) - protocol AN072-008: an interim analysis.
Movement Disorders 1995;10:2874 (abstract).
∗ Koller M, Wallace JD, Willmer-Hulme A, Chiang P,
Murray JJ. Evaluation of Neurobloc (Botulinum toxin type
B) efficacy in patients with cervical dystonia. Movement
Disorders 2000;15 (Suppl 2):31.
Chinnapongse 2010 {published data only}
Chinnapongse R, Pappert EJ, Evatt M, Freeman A,
Birmingham W. An open-label, sequential dose-escalation,
safety, and tolerability study of rimabotulinumtoxinB in
subjects with cervical dystonia. International Journal of
Neuroscience 2010;120(11):703–10.
Cullis 2000 {published data only}
Cullis PA, Barnes M, Duane D, Chen RE, Freeman A,
Fross R, et al. Safety and tolerability of repeated doses
of Neurobloc (Botulinum toxin type B) in patients with
22Botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
cervical dystonia: an open-label, dose-escalation study.
Movement Disorders 2000;15 (Suppl 2):29.
Dressler 2005 {published data only}
Dressler D, Bigalke H. Botulinum toxin type B de novo
therapy of cervical dystonia: frequency of antibody induced
therapy failure. Journal of neurology 2005;252(8):904–7.
Jacob 2003 {published data only}
Jacob CI. Botulinum toxin type B - onset, duration,
and efficacy: comparing dilution with preserved versus
nonpreserved saline. Cosmetic Dermatology 2003;16(7):25.
Jankovic 2006 {published data only}
Jankovic J, Hunter C, Dolimbek DZ, Dolimbek GS, Adler
CH, Brashear A, et al. Clinico-immunologic aspects of
botulinum toxin type B treatment of cervical dystonia.
Neurology 2006;67(12):2233–5.
Lew 2002 {published data only}
Lew MF. Botulinum toxin type B: An effective treatment for
alleviating pain associated with cervical dystonia. Journal of
Back and Musculoskeletal Rehabilitation 2002;16(1):3–9.
Truong 1997 {published data only}
Truong DD, Cullis PA, O’Brien CF, Koller M, Villegas TP,
Wallace JD. BotB (Botulinum toxin type B): Evaluation of
safety and tolerability in Botulinum type A-resistant cervical
dystonia patients (preliminary study). Movement Disorders
1997;12(5):772–5.
Additional references
Abrams 2005
Abrams KR, Gillies CL, Lambert PC. Meta-analysis of
heterogeneously reported trials assessing change from
baseline. Statistics in Medicine 2005;24:3823–44.
Albanese 2013
Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn
S, Fung VS, et al. Phenomenology and classification of
dystonia: a consensus update. Movement Disorders 2013;28
(7):863–73.
Altman 2002
Altman DG, Deeks JJ. Meta-analysis, Simpson’s paradox,
and the number needed to treat. BMC Medical Research
Methodology 2002;2:3.
Antonucci 2008
Antonucci F, Rossi C, Gianfranceschi L, Rossetto O,
Caleo M. Long-distance retrograde effects of botulinum
neurotoxin. Journal of Neuroscience 2008;28:3689-96.
Balint 2015
Balint B, Bhatia KP. Isolated and combined dystonia
syndromes - an update on new genes and their phenotypes.
European Journal of Neurology 2015;22(4):610–7.
Benecke 2012
Benecke R. Clinical relevance of Botulinum toxin
immunogenicity. BioDrugs 2012 Apr;26(2):e1–e9.
Boroff 1975
Boroff DA, Chen GS. On the question of permeability of
the blood-brain barrier to botulinum toxin. Int Arch Allergy
ApplImmunol. 1975;48:495-504.
Brashear 2008
Brashear A. Botulinum toxin serotype A for cervical
dystonia - an assessment. US Neurol 2008;4(2):58–61.
Brin 2008
Brin MF, Comella CL, Jankovic J, Lai F, Naumann M,
CD-017 BoNTA Study Group. Long-term treatment
with botulinum toxin type A in cervical dystonia has low
immunogenicity by mouse protection assay. Movement
Disorders 2008 Jul;23(10):1353–60.
Brozek 2006
Bro ek JL, Guyatt GH, Schünemann HJ. How a well-
grounded minimal important difference can enhance
transparency of labelling claims and improve interpretation
of a patient reported outcome measure. Health and Quality
of Life Outcomes 2006;4:69.
Chan 1991
Chan J, Brin MF, Fanh S. Idiopathic cervical dystonia:
clinical characteristics. Movement Disorders 1991;6:119–26.
Cohen 1988
Cohen J. Statistical power analysis in the behavioral sciences.
Statistical Power Analysis in the Behavioral Sciences. 2nd
Edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc.,
1988.
Comella 2015
Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA,
Zurowski M, et al. Development of the Comprehensive
Cervical Dystonia Rating Scale: Methodology. Movement
Disorders 2015;2(2):135–41.
Consky 1994
Consky ES, Lang AE. Clinical assessments of patients
with cervical dystonia. In: Jankovic J, Hallett M editor
(s). Therapy with botulinum toxin. New York, NY: Marcel
Dekker, Inc, 1994:211–37.
de Paiva 1999
de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO.
Functional repair of motor endplates after botulinum
neurotoxin type A poisoning: biphasic switch of synaptic
activity between nerve sprouts and their parent terminals.
Proc Natl Acad Sci USA. 1999;96:3200-5.
Defazio 2013
Defazio G, Jankovic J, Giel JL, Papapetropoulos S.
Descriptive epidemiology of cervical dystonia. Tremor Other
Hyperkinet Mov 2013;3:tre–03-193-4374-2.
Duchen 1971
Duchen LW. An electron microscopic study of the changes
induced by botulinum toxin in the motor end-plates of slow
and fast skeletal muscle fibres of the mouse. J Neurol Sci.
1971;14:47–60.
Edwards 2000
Edwards IR, Aronson JK. Adverse drug reactions:
definitions, diagnosis, and management. Lancet 2000 Oct
7;356(9237):1255–1259.
Eleopra 1997
Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De
Grandis D. Botulinum neurotoxin serotype C: a novel
23Botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
effective botulinum toxin therapy in human. Neuroscience
Letters 1997;224(2):91–4.
ESDE 2000
Epidemiological Study of Dystonia in Europe (ESDE)
Collaborative Group. A prevalence study of primary
dystonia in eight European countries. Journal of Neurology
2000;247:787–92.
Fabbri 2015
Fabbri M, Leodori G, Fernandes RM, Bhidayasiri R,
Marti MJ, Colosimo C, et al. Neutralizing antibody and
Botulinum toxin therapy: a sSystematic review and meta-
analysis. Neurotox Res 2015;29:105–117. [PUBMED:
26467676]
Filippi 1993
Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E.
Botulinum A toxin effects on rat jaw muscle spindles. Acta
Otolaryngol. 1993;113:400-4.
Follmann 1992
Follmann D, Elliott P, Suh I, Cutler J. Variance imputation
for overviews of clinical trials with continuous response.
Journal of Clinical Epidemiology 1992;45:769–773.
Foltz 1959
Foltz EL, Knopp LM, Ward AA. Experimental spasmodic
torticollis. Journal of Neurosurgery 1959;16:55–72.
Frevert 2010
Frevert J, Dressler D. Complexing proteins in botulinum
toxin type A drugs: a help or a hindrance?. Biologics: Targets
& Therapy 2010 Dec;4:325–332.
Greene 1993
Greene PE, Fahn S. Use of botulinum toxin type F injections
to treat torticollis in patients with immunity to botulinum
toxin type A. Movement Disorders 1993;8(4):479–83.
Hallett 1998
Hallett M. The neurophysiology of dystonia. Arch Neurol
1998 May;55(5):601–603.
Hanna 1998
Hanna PA, Jankovic J. Mouse bioassay versus Western blot
assay for botulinum toxin antibodies: correlation with
clinical response. Neurology 1998 Jun;50(6):1624–9.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7414):557–60.
Higgins 2011a
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter
8: Assessing risk of bias in included studies. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Higgins 2011b
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter
16: Special topics in statistics. In: Higgins JPT, Green
S (editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Holland 1981
Holland RL, Brown MC. Nerve growth in botulinum toxin
poisoned muscles. Neuroscience. 1981;6:1167-79.
Jahnanshani 1990
Jahnanshani M, Marion M-H, Marsden CD. Natural
history of adult-onset idiopathic torticollis. Archives of
Neurology 1990;47:548–52.
Jankovic 2004
Jankovic J. Botulinum toxin in clinical practice. J Neurol
Neurosurg Psychiatry 2004;75(7):951–957.
Juzans 1996
Juzans P, Comella J, Molgo J, Faille L, Angaut-Petit D.
Nerve terminal sprouting inbotulinum type-A treated
mouse levator auris longus muscle. Neuromuscul Disord.
1996;6(3):177–85.
Lange 2009
Lange O, Bigalke H, Dengler R, Wegner F, deGroot M,
Wohlfarth K. Neutralizing antibodies and secondary
therapy failure after treatment with botulinum toxin type
A: much ado about nothing?. Clin Neuropharmacol 2009
Jul–Aug;32(4):213–8.
Macefield 2014
Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance
RN, Brookes ST, Set al. Developing core outcomes sets:
methods for identifying and including patient-reported
outcomes (PROs). Trials 2014;15:49.
Matak 2014
Matak I, Lackovi Z. Botulinum toxin A, brain and pain.
Prog Neurobiol. 2014 Aug–Sep;119-120:39-59.
Matak 2015
Matak I, Lackovi Z. Botulinum neurotoxin type A:
Actions beyond SNAP-25?. Toxicology. 2015;335:79–84.
Michiels 2005
Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon
JP. Meta-analysis when only the median survival times are
known: a comparison with individual patient data results.
Int J Technol Assess Health Care 2005;21(1):119–25.
Muller 2009
Müller K, Mix E, Adib Saberi F, Dressler D, Benecke R.
Prevalence of neutralising antibodies in patients treated with
botulinum toxin type A for spasticity. J Neural Transm 2009
May;116(5):579–85.
Palomar 2012
Palomar FJ, Mir P. Neurophysiological changes after
intramuscular injection of botulinum toxin. Clin
Neurophysiol. 2012;123:23:54-60.
Pellizzari 1999
Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus
and botulinum neurotoxins: mechanism of action and
therapeutic uses. Philos Trans R Soc Lond B Biol Sci. 1999;
354:259-68.
24Botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Peters 2006
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L.
Comparison of two methods to detect publication bias in
meta-analysis. JAMA. 2006;295(6):676–80.
RevMan 2014 [Computer program]
The Nordic Centre, The Cochrane Collaboration. Review
Manager (RevMan). Version 5.3. Copenhagen: The
Nordic Centre, The Cochrane Collaboration, 2014.
Rosales 1996
Rosales RL, Arimura K, Takenaka S, Osame M. Extrafusal
and intrafusal muscle effects in experimental botulinum
toxin-A injection. Muscle Nerve. 1996;19:488-96.
Rosales 2010
Rosales RL, Dressler D. On muscle spindles, dystonia and
botulinum toxin. Eur J Neurol. 2010;17:71-80.
Simpson 2004
Simpson LL. Identification of the major steps in botulinum
toxin action. Annu Rev Pharmacol Toxicol. 2004;44:
167–93.
Smeeth 1999
Smeeth L, Haines A, Ebrahim S. Numbers needed to treat
derived from meta-analysis - sometimes informative, usually
misleading. BMJ 1999;318(7197):1548–51.
Steeves 2012
Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T.
The prevalence of primary dystonia: A systematic review
and meta-analysis. Movement Disorders. 2012 Dec;27(14):
1789–96.
Sterne 2001
Sterne JA, Egger M. Funnel plots for detecting bias in meta-
analysis: guidelines on choice of axis. J Clin Epidemiol.
2001;54(10):1046–1055.
Sterne 2011
Sterne JAC, Egger M, Moher D (editors). Chapter 10:
Addressing reporting biases. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Intervention. Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Tugwell 2007
Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L.
OMERACT: an international initiative to improve outcome
measurement in rheumatology. Trials 2007;8:38.
Walker 2014
Walker TJ, Dayan SH. Comparison and overview of
currently available neurotoxins. J Clin Aesthet Dermatol.
2014;7(2):31–9.
Zoons 2012
Zoons E, Dijkgraaf MGW, Dijk JM, vVan Schaik IN,
Tijssen MA. Botulinum toxin as treatment for focal
dystonia: a systematic review of the pharmaco-therapeutic
and pharmaco-economic value. Neurology Dec 2012;259
(12):2519-2526.
References to other published versions of this review
Costa 2004
Costa J, Borges A, Espírito-Santo C, Ferreira J, Coelho
M, Moore P, Sampaio C. Botulinum toxin type A versus
botulinum toxin type B for cervical dystonia. Cochrane
Database of Systematic Reviews 2004, Issue 1. [DOI:
10.1002/14651858.CD004314.pub2]
∗ Indicates the major publication for the study
25Botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brashear 1999
Methods Randomised, multi-centre, double-blind, three-arm, parallel, phase III study
Method of randomisation: master randomisation tables generated by an independent
organisation
Data analysed on intention-to-treat basis
Location: multiple centres in the USA
Duration: 16 weeks
Participants 109 participants were enrolled
Placebo arm: 36 participants (2 withdrawals: 5.5%), 21 participants were female and
15 were male, mean age was 54.3 ± 12.2 (SD) years, ethnicity: 32 white and 4 black,
mean duration of symptoms not stated, mean TWSTRS-Total score at baseline: 43.6 ±
9 (SD)
BtB 5000 U arm: 36 participants (1 withdrawal: 2.7%), 18 participants were female
and 18 were male, mean age was 57.6 ± 12.3 (SD) years, ethnicity: 35 white and 1 black,
mean duration of symptoms not stated, mean TWSTRS-Total score at baseline: 46.4 ±
10.4 (SD)
BtB 10,000 U arm: 37 participants (1 withdrawal: 2.7%), 28 participants were female
and 9 were male, mean age was 56.2 ± 11.8 (SD), ethnicity: 33 white and 4 black, mean
duration of symptoms not stated, mean TWSTRS-Total score at baseline: 46.9 ± 9.6
(SD)
Inclusion criteria: Cervical Dystonia (CD) for at least 1 year with involvement of two
or more neckmuscles and responsive to BtA treatment; TWSTRS-Total score at baseline
of at least 20 with a TWSTRS-Severity score of at least 10, a TWSTRS-Disability score
of at least 3, and a TWSTRS-Pain score of at least 1
Age more than 17 years-old
Weight more than 45 Kg
Physical and neurological examinations and laboratory tests acceptable clinically
Informed consent.
Exclusion criteria:Bt injections in the previous 4months for CD; previous participation
in BtB trial; neck contractures or cervical spine disease; pure retrocollis or anterocollis;
use of drugs that could interfere with efficacy and security evaluations (e.g., narcotics,
benzodiazepines); acute or chronic medical condition or known drug hypersensitivity to
the study drug; history of myotomy or denervation surgery of the neck; previous tetanus
toxoid in the last 4 months; history of clinically persistent neurological or neuromuscular
disorder; and women of child-bearing potential who were pregnant or breast-feeding
Interventions The study drug (BtB) was provided by Athenas Neurociences, Inc in vials that contained
placebo or 5000 U in a 1 ml sterile solution, buffered to a pH of 5.5, and refrigerated
Each participant was randomly assigned to one of the three groups: placebo, 5000 U
of BtB or 10,000 U BtB. A total of 2 ml of the study drug was injected into two
to four involved CD muscles selected by the investigator with or without the use of
electromyography. Based on the investigator’s judgement, the proportionate volume per
muscle was divided and injected into one to five sites. Each participant received only
one treatment
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Brashear 1999 (Continued)
Outcomes The primary efficacy outcome was the change in TWSTRS-Total score at week 4
Secondary efficacy outcomes included changes in two visual analogue scales (Patient
Global Assessment of Change and Principal investigator Global Assessment of Change)
at week 4, and change in TWSTRS-Total score at weeks 8 and 12
Tertiary efficacy outcomes included change in visual analogue scale Patient Analog Pain
Assessment at week 4, and changes in the TWSTRS sub-scales scores at weeks 4 and 16.
For all outcomes data were collected at treatment visit (day 1), and at weeks 2, 4, 8, 12,
and 16 (termination). Adverse events data were collected at each visit
Notes Reasons for withdrawal: in the placebo group one discontinued the study because of
lack of effect and one participant due to request related to a new job; in the 5000 U
group one participant discontinued because of lack of effect; in the 10,000 U group one
participant discontinued because of a serious adverse effect (death following coronary
artery bypass surgery). Results were presented as variance of the means of the various
outcome scales scores without individual data. An estimation of duration of treatment
effect was made based on time to return to baseline TWSTRS-Total score
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Master randomisation tables were gener-
ated by an independent organisation (Phar-
maceutical Research Associates).”
Method of randomisation not specified
Allocation concealment (selection bias) Low risk “Investigators, patients, and the sponsor
were blinded to drug assignment until after
the database was locked and analyzed.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The study drug was provided by Athena
Neurosciences, Inc. in 3.5-mL vials con-
taining either 5000U of NeurBloc or
placebo (same solution without toxin).”
Study described as double blind
Blinding of outcome assessment (detection
bias)
Objective Outcomes
Low risk “The principal investigator (PI) completed
all screening, day 1 activities, and subse-
quently completed only the TWSTRS and
PI Global Assessment of Change. After
study-drug injection, no other information
about the patient was provided to or dis-
cussed with the PI.”
Blinding of outcome assessment (detection
bias)
Subjective Outcomes
Unclear risk “The administrative investigator (...) con-
ducted all other activities for weeks 1 to 12
and termination visit.”
Although placebo was identical to inter-
vention, the fact that all of the partici-
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Brashear 1999 (Continued)
pants had previously been treated with bo-
tulinum toxins could have led to a degree
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation exclusions were low
and distributed evenly between groups
(BTB 5000 U group = 1; BTB 10,000 U
group = 1; Placebo group = 2), and the rea-
sons were described
Selective reporting (reporting bias) Low risk “The ITT dataset was used for all analyses.
”
The usual and more clinically relevant out-
comes that are usually evaluated in inter-
vention trials for this condition were re-
ported in this study
Enriched population - preferential enrol-
ment of positive responders
High risk “Patients were eligible (...) if their CD con-
tinued to respond to BoNT/A treatment.”
Enriched population - exclusion of poor re-
sponders
High risk “Patients were excluded if they (...) had
pure anterocollis or retrocollis.”
Other issues High risk “Supported by a grant from Athena Neu-
rosciences, Inc.”
Brin 1999
Methods Randomised, multicenter, placebo-controlled, double-blind, two-arm, parallel, phase III
study
Method of randomisation: master randomisation tables generated by an independent
organisation
Data analysed on an intention-to-treat basis
Location: seven centres in the USA
Duration: 16 weeks
Participants 77 participants were enrolled
Placebo arm: 38 participants (1 withdrawal: 2.6%); 26 participants were female and 12
were male; mean age was 52.6 ± 13.3 (SD) years; ethnicity: all participants were White;
mean duration of symptoms not stated; mean TWSTRS-Total score at baseline: 51.2 ±
9.5 (SD)
BtB 10,000 U arm: 39 participants (0 withdrawals); 27 participants were female and
12 were male; mean age was 56.6 ± 11.7 (SD); ethnicity: all participants were White;
mean duration of symptoms not stated; mean TWSTRS-Total score at baseline: 52.8 ±
8.6 (SD)
Inclusion criteria: Cervical Dystonia (CD) for at least one year of duration with in-
volvement of two or more neck muscles, and considered clinically non-responsive to
BtA treatment with an appropriate frontalis-type A test result; TWSTRS-Total score
at baseline of at least 20 with a TWSTRS-Severity score of at least 10, a TWSTRS-
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Brin 1999 (Continued)
Disability score of at least 3, and a TWSTRS-Pain score of at least 1
Age more than 17 years-old
Weight more than 45 Kg
Physical and neurological examinations and laboratory tests acceptable clinically
Informed consent
Exclusion criteria: Bt injections in the previous four months for CD; previous par-
ticipation in a BtB trial; neck contractures or cervical spine disease that limit range of
motion; pure retrocollis or anterocollis; use of drugs that could interfere with efficacy
and security evaluations (e.g., narcotics, benzodiazepines); previous tetanus toxoid in the
last 4 months; use of any investigational drug or device within 30 days of entry into the
study; current acute or chronic medical condition or known drug hypersensitivity to the
study drug that would preclude Bt injections; history of myotomy or denervation surgery
of the neck; history of clinically persistent neurological or neuromuscular disorder; and
women of child-bearing potential who were pregnant or breast-feeding
Interventions The study drug (BtB) was provided by Athenas Neurociences, Inc in vials that contained
placebo or 5000 U of BtB in a 1 ml sterile solution. Each participant was randomly
assigned to one of the 2 groups: placebo or 10,000 U BtB. A total of 2 ml of the
study drug was injected into 2 to 4 involved CD muscles selected by the investigator
with or without the use of electromyography. Based on the investigator judgement, the
proportionate volume per muscle was divided and injected into one to five sites. Each
participant received only one treatment
Outcomes The primary efficacy outcome was the change in TWSTRS-Total score at week 4
Secondary efficacy outcomes included changes in two visual analogue scales (Patient
Global Assessment of Change and Principal investigator Global Assessment of Change)
at week 4, and change in TWSTRS-Total score at weeks 8 and 12
Tertiary efficacy outcomes included change in visual analogue scale Patient Analog Pain
Assessment at week 4, changes in the TWSTRS subscales scores at week 4, and change
in TWSTRS-Total score at week 16
All outcomes data were collected at treatment visit (day 1), and at weeks 2, 4, 8, 12, and
16 (termination). The results of the primary outcome were used to assess the duration
of clinical benefit. Adverse events data were collected at each visit
Notes Reasons for withdrawal: in the placebo group 1 discontinued the study because of an
adverse effect
Results are presented as variance of themeans of the various outcome scales scores without
individual data. An estimation of duration of treatment effect was made based on time
to return to baseline TWSTRS-Total score
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Master randomisation tables were gener-
ated by an independent organisation (Phar-
maceutical Research Associates).”
Method of randomisation not specified
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Brin 1999 (Continued)
Allocation concealment (selection bias) Low risk “Investigators, patients, and the sponsor
were blinded to drug assignment until after
the database was locked and analyzed”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The study drug, provided by AthenaNeu-
rosciences, Inc. in 3.5-mL vials contain-
ing either 5000 U of NeurBloc or placebo
(same solution without toxin).”
Study described as double blind
Blinding of outcome assessment (detection
bias)
Objective Outcomes
Low risk “The principal investigator (PI) performed
all screening assessments, (...) and per-
formed the injection, in addition to acquir-
ing all TWSTRS scores and the PI Global
Assessment of Change.”
Blinding of outcome assessment (detection
bias)
Subjective Outcomes
Unclear risk “The administrative investigator (...) per-
formed all other activities for each visit (in-
cluding adverse events collection and as-
sessment. Patients were instructed not to
divulge any AE information to the princi-
pal investigator.”
Although placebo was identical to inter-
vention, the fact that all of the partici-
pants had previously been treated with bo-
tulinum toxins could have led to a degree
of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Post-randomisation exclusions were low
(Placebo group = 1), and the reasons were
described
Selective reporting (reporting bias) Low risk “The ITT dataset was used for all analyses.
”
The usual and more clinically relevant out-
comes that are usually evaluated in inter-
vention trials for this condition were re-
ported in this study
Enriched population - preferential enrol-
ment of positive responders
Low risk Trial in botulinum toxin type A-non-re-
sponsive CD
Enriched population - exclusion of poor re-
sponders
High risk “Patients were excluded if they (...) had
pure anterocollis or retrocollis.”
Other issues High risk “Supported by a grant from Athena Neu-
rosciences, Inc.”
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Kaji 2013
Methods Randomised, double-blind, four-arm, parallel, study
Method of randomisation: random sequence was generated by independent organisation,
but randomisation sequence was not described
Data analysed on an intention-to-treat basis
Location: Japan
Duration: 16 weeks
Participants 130 participants were administered Bt
Placebo arm: 33 participants (4 withdrawals, 2 of them before the study medication:
12.1%), 12 participants were female and 21 were male, mean age was 49.7 ± 13.6 (SD)
years, ethnicity not stated, mean duration of symptoms: 7.84 ± 7.1 (SD) years, mean
TWSTRS-Total score at baseline: 44.0 ± 8.8 (SD)
BtB 2500 U arm: 34 participants (1 withdrawal: 1.94%), 11 participants were female
and 23 were male, mean age was 50.8 ± 14.7 (SD) years, ethnicity not stated, mean
duration of symptoms: 8.53 ± 7.41 (SD) years, mean TWSTRS-Total score at baseline:
43.9 ± 7.5 (SD)
BtB 5000 U arm: 32 participants (2 withdrawals, 1 of them before study medication:
6.25%), 15 participants were female and 17 were male, mean age was 46.8 ± 12.5 (SD)
years, ethnicity not stated, mean duration of symptoms: 5.58 ± 5.90 (SD) years, mean
TWSTRS-Total score at baseline: 43.2 ± 9.7 (SD)
BtB 10,000 U arm: 31 participants (2 withdrawals: 6.45%), 14 participants were female
and 17 were male, mean age was 50.0 ± 12.6 (SD) years, ethnicity not stated, mean
duration of symptoms: 6.76 ± 5.10 (SD) years, mean TWSTRS-Total score at baseline:
42.4 ± 8.8 (SD)
Interventions Study drug (BtB) and placebo were prepared by mixing three unlabelled vials. Each
participant was randomly assigned to one of the 4 groups: placebo, 2500 U of BtB, 5000
U of BtB, or 10,000 U BtB. Each participant received only one treatment
The provider of the study drug is not stated, though members of Eisai Co., Ltd were
included as authors
Outcomes The primary efficacy outcome was the change in TWSTRS-Total score from baseline at
week 4
Secondary efficacy outcomes included changes in two visual analogue scales (Patient
Global and Pain Assessment of Change, and Principal investigator Global Assessment of
Change), and change in TWSTRS severity, disability and pain score at week 4. Adverse
effects were collected
Notes Reasons for withdrawals: 3 of the 133 participants withdrew before the start of study
medication (2 participants in placebo group and 1 participant in 5000 U group). Two
of these withdrawals were due to participant request, and the other participant did not
attend hospital
The motive of each participant was not reported
After medication, 2 participants in placebo group, 1 participant in 2500 U group and 1
participant in 5000 U group requested to discontinue the study; and 2 participants in
10,000 U group moved to another treatment because of lack of effect
There were no adverse events that led to death, serious disorders or study withdrawal.
Results are presented as variance of themeans of the various outcome scales scores without
individual data
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Kaji 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence was not described
Allocation concealment (selection bias) Low risk Randomisation was generated by an inde-
pendent organisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo and active drug were prepared by
mixing three unlabelled vials
Blinding of outcome assessment (detection
bias)
Objective Outcomes
Unclear risk No description of the process
Blinding of outcome assessment (detection
bias)
Subjective Outcomes
Unclear risk No description of the process
Incomplete outcome data (attrition bias)
All outcomes
Low risk The missing data maximum ratio was 11%
in placebo group and balanced across group
Selective reporting (reporting bias) Low risk All outcomes in methods were reported
Enriched population - preferential enrol-
ment of positive responders
Low risk The study allowed the entrance of BtA-
naive and -non-responsive patients
Enriched population - exclusion of poor re-
sponders
Low risk Enrolled participants were consistent with
review protocol
Other issues High risk No description of funding, but members of
Eisai Co., Ltd were included as authors
Lew 1997
Methods Randomised, multicenter, placebo-controlled, double-blind, four-arm, parallel, phase II
study
Method of randomisation: not described
Data analysed on an intention-to-treat basis
Location: multiple centres in the USA
Duration: 16 weeks
Participants 122 participants aged 19 to 81 years were enrolled. 67% of the participants were female.
97% were White, 1.6% were Hispanic and 1.6% were Afro-American. 79% were re-
sponsive to BtA treatment and 21% were BtA-non-responsive
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Lew 1997 (Continued)
Placebo arm: 30 participants, mean duration of symptoms not stated, mean TWSTRS-
Total score was 45.5
BtB 2500 U arm: 31 participants, mean duration of symptoms not stated, mean TW-
STRS-Total score at baseline was 45.6
BtB 5000 U arm: 31 participants, mean duration of symptoms not stated, mean TW-
STRS-Total score at baseline was 45.2
BtB 10,000 U arm: 30 participants, mean duration of symptoms not stated, mean
TWSTRS-Total score at baseline was 47.5
Inclusion criteria: Idiopathic Cervical Dystonia (CD) of 1 to 10 years’ duration with
involvement of 2 or more neck muscles, either responsive or non--responsive to BtA
treatment; TWSTRS-Total score at baseline of at least 20 with a TWSTRS-Severity score
of at least 10, a TWSTRS-Disability score of at least 3, and a TWSTRS-Pain score of at
least 1
Age more than 17 years-old
Weight more than 45 Kg
Physical and neurological examinations and laboratory tests acceptable clinically
Informed consent
Exclusion criteria: Primary nonresponder to BtA injection; Bt injections in the previous
4 months for CD; no return to inter-treatment baseline clinical dystonia status; neck
contractures or cervical spine disease that limit range of motion; pure retrocollis or
anterocollis; use of drugs that could interfere with efficacy and security evaluations (e.
g., narcotics, benzodiazepines); use of aminoglycosides or any investigational drug or
device within 30 days of entry into the study; current acute or chronic medical condition
or known drug hypersensitivity to the study drug that would preclude Bt injections;
history of myotomy or denervation surgery of the neck; history of clinically persistent
neurological or neuromuscular disorder; and women pregnant or nursing
Interventions The study drug (BtB) was provided by Athenas Neurociences, Inc in vials that contained
placebo, 2500 U or 5000 U of BtB in a 1 ml sterile solution. Each participant was
randomly assigned to one of the 4 groups: placebo, 2500 U, 5000 U or 10,000 U BtB.
A total of 2 ml of the study drug was injected into 2 to 4 involved CD muscles selected
by the investigator with or without the use of electromyography. The study drug (in a
volume of 2 ml) could be further diluted by adding 0.9% sterile normal saline without
preservative up to a maximal final volume of 5 ml. Each participant received only one
treatment
Outcomes The primary efficacy outcome was the change in TWSTRS-Total score at week 4
Secondary efficacy outcomes included changes in three visual analogue scales (Patient
Global Assessment ofChange, PatientAnalogPainAssessment, andPrincipal investigator
Global Assessment of Change) at week 4, changes in the TWSTRS subscales scores at
week 4, change in TWSTRS-Total score at week 8, 12 and 16, and change in Sickness
Impact Profile (SIP) at week 4.With the exception of SIP all outcomes datawere collected
at treatment visit (day 1), and at weeks 2, 4, 8, 12, and 16 (termination). The results of
the primary outcome were used to assess the duration of clinical benefit. Adverse events
data were either spontaneously reported by participants or elicited by the investigators
at each visit. BtB antibodies were determined by ELISA at baseline and week 4
Notes All participants completed the study per the protocol
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Lew 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not specified
Allocation concealment (selection bias) Unclear risk Method of concealment not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The study drug was provided by Athena
Neurosciences, Inc. in 5-mL vials contain-
ing either 2500U or 5000U of NeurBloc in
1-mL sterile solution. The same sterile so-
lution (without toxin) was used as placebo.
”
Blinding not specified although study de-
scribed as double blind
Blinding of outcome assessment (detection
bias)
Objective Outcomes
Unclear risk Blinding not specified although study de-
scribed as double blind
Blinding of outcome assessment (detection
bias)
Subjective Outcomes
Unclear risk Blinding not specified although study de-
scribed as double blind
Although placebo was identical to inter-
vention, the fact that all of the partici-
pants had previously been treated with bo-
tulinum toxin could have led to a degree of
bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All patients completed the study per pro-
tocol.”
Selective reporting (reporting bias) Low risk “The primary analyses included all patients
who entered the study, received the study
drug, and had at least one visit during
which efficacy data were obtained.”
The expected outcomes that are usually
evaluated in intervention trials for this con-
dition were reported in this study
Enriched population - preferential enrol-
ment of positive responders
Low risk “Patients were excluded if they were a pri-
mary nonresponder to type A toxin injec-
tion.”
Both BtA-responsive and BtA-non-respon-
sive patients were enrolled
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Lew 1997 (Continued)
Enriched population - exclusion of poor re-
sponders
High risk “Patients were excluded if they (...) had
pure anterocollis or retrocollis.”
Other issues Unclear risk Not stated
SD: Standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
AN072-008 1995 This is a randomised, multicentre (USA), double-blind, placebo-controlled, single dose, four-arm, dose-
finding parallel group design study. The follow-up was 16 weeks. 85 participants were enrolled. Mean age
was 53.2 years (18-80). 38% of the participants were male and 62% were female. 95% were White. The
study included both BtA-responsive and -non-responsive participants. The study drug (BtB) was provided
by Athenas Neurociences, Inc. Each participant was randomly assigned to one of the 4 groups: placebo, 400
U, 1200 U or 2400 U of BtB. The study drug was injected into 2 to 4 superficial neck and/or shoulder
muscle groups. Each participant received only one treatment. The primary efficacy outcome was the change
in TWSTRS-Total score (range 0 to 87). One participant in the placebo group withdrew because of an adverse
effect. This study was excluded because data was not available
Chinnapongse 2010 This trial was a sequential dose-escalation, safety, and tolerability study of BtB in subjects with cervical dystonia.
Participants were assigned to one of three doses of BtB: 10,000 U, 12,500 U, and 15,000 U. Efficacy was
evaluated using TWSTRS total and subscale scores and three VAS. The study was excluded for being open-
label and not having a placebo group
Cullis 2000 145 participants with cervical dystonia were enrolled. The study was open-label and compared three different
doses of BtB without a placebo group
Dressler 2005 This was a non-randomised, non-controlled study enrolling 9 participants with cervical dystonia aiming to
test the immunogenicity of botulinum toxin type B in patients naïve to botulinum toxin treatment
Jacob 2003 This was a double-blind study evaluating botulinum toxin type B diluted with preserved versus nonpreserved
isotonic saline. Ten participants were treated on each half of the frontalis muscle with a total of 2400 units
of botulinum toxin type B diluted either with preserved or nonpreserved saline. In addition to studying a
different population, the study is not placebo-controlled as both arms are treated with BtB
Jankovic 2006 This was a non-randomised, non-controlled, multicenter study enrolling 100 participants with cervical dys-
tonia aiming to test the immunogenicity of botulinum toxin type B
Lew 2002 This paper describes an analysis of a subset of efficacy data from two randomised, double blind, placebo-
controlled clinical trials already included in this systematic review (Brashear 1999; Brin 1999)
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(Continued)
Truong 1997 12 participants with cervical dystonia were enrolled. The study was open-label and compared different doses
of BtB without a placebo group
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D A T A A N D A N A L Y S E S
Comparison 1. Botulinum toxin type B vs Placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cervical dystonia
improvement as assessed
with TWSTRS: change from
baseline to week 4
3 Mean Difference (Fixed, 95% CI) 6.78 [4.54, 9.01]
2 Overall cervical dystonia
improvement as assessed
with TWSTRS: change from
baseline to week 4 - Doses
subgroup analysis
4 Mean Difference (Fixed, 95% CI) Subtotals only
2.1 2500 units 2 Mean Difference (Fixed, 95% CI) 6.95 [3.70, 10.21]
2.2 5000 units 3 Mean Difference (Fixed, 95% CI) 6.10 [3.40, 8.81]
2.3 10,000 units 4 Mean Difference (Fixed, 95% CI) 8.72 [6.35, 11.10]
3 Overall cervical dystonia
improvement as assessed
with TWSTRS: change
from baseline to week
4 - BtA-responsive vs
BtA-non-responsive subgroup
analysis
2 Mean Difference (Fixed, 95% CI) 7.56 [4.41, 10.71]
3.1 BtA-responsive 1 Mean Difference (Fixed, 95% CI) 9.0 [4.46, 13.54]
3.2 BtA-non-responsive 1 Mean Difference (Fixed, 95% CI) 6.22 [1.83, 10.60]
4 Proportion of participants with
adverse events
2 186 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.97, 1.23]
5 Proportion of participants with
adverse events - doses subgroup
analysis
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 5000 U 1 72 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.89, 1.29]
5.2 10,000 U 2 150 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.89, 1.33]
6 Proportion of participants with
adverse events - BtA-responsive
vs BtA-non-responsive
subgroup analysis
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 BtA-responsive 1 73 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.79, 1.20]
6.2 BtA-non-responsive 1 77 Risk Ratio (M-H, Random, 95% CI) 1.19 [1.03, 1.37]
7 Subjective change as assessed by
the participant at week 4
3 316 Std. Mean Difference (IV, Fixed, 95% CI) 0.86 [0.61, 1.10]
8 Subjective change as assessed by
the clinician at week 4
3 316 Std. Mean Difference (IV, Fixed, 95% CI) 0.80 [0.55, 1.04]
9 Subjective change as assessed
by the participant at week 4 -
doses subgroup analysis
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 2500 U 1 67 Mean Difference (IV, Fixed, 95% CI) 12.30 [4.21, 20.39]
9.2 5000 U 2 137 Mean Difference (IV, Fixed, 95% CI) 9.71 [4.05, 15.37]
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9.3 10,000 U 3 214 Mean Difference (IV, Fixed, 95% CI) 15.12 [10.32, 19.91]
10 Subjective change as assessed by
the clinician at week 4 - doses
subgroup analysis
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 2500 U 1 67 Mean Difference (IV, Fixed, 95% CI) 8.60 [1.46, 15.74]
10.2 5000 U 2 137 Mean Difference (IV, Fixed, 95% CI) 10.84 [5.65, 16.04]
10.3 10,000 U 3 214 Mean Difference (IV, Fixed, 95% CI) 13.22 [9.39, 17.05]
11 Subjective change as assessed
by the participant at week
4 - BtA-responsive vs
BtA-non-responsive subgroup
analysis
2 186 Mean Difference (IV, Fixed, 95% CI) 19.83 [13.61, 26.05]
11.1 BtA-responsive 1 109 Mean Difference (IV, Fixed, 95% CI) 19.03 [10.41, 27.65]
11.2 BtA-non-responsive 1 77 Mean Difference (IV, Fixed, 95% CI) 20.70 [11.73, 29.67]
12 Subjective change as assessed
by the clinician at week 4
- BtA-non-responsive vs
-responsive subgroup analysis
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 BtA-responsive 1 109 Mean Difference (IV, Fixed, 95% CI) 12.74 [5.83, 19.65]
12.2 BtA-non-responsive 1 77 Mean Difference (IV, Fixed, 95% CI) 12.70 [7.04, 18.36]
13 Cervical dystonia associated
pain: change from baseline
to week 4 as assessed with
TWSTRS
2 Mean Difference (Fixed, 95% CI) 2.20 [1.25, 3.15]
14 Cervical dystonia associated
pain: change from baseline
to week 4 as assessed with
TWSTRS - doses subgroup
analysis
3 Mean Difference (Fixed, 95% CI) Subtotals only
14.1 2500 units 2 Mean Difference (Fixed, 95% CI) 2.58 [1.33, 3.84]
14.2 5000 units 2 Mean Difference (Fixed, 95% CI) 2.05 [0.83, 3.27]
14.3 10,000 units 3 Mean Difference (Fixed, 95% CI) 3.07 [1.99, 4.14]
15 Cervical dystonia associated
pain: change from baseline to
week 4 as assessed with validated
scales - BtA-responsive vs
BtA-non-responsive subgroup
analysis
2 Std. Mean Difference (Fixed, 95% CI) 0.96 [0.65, 1.27]
15.1 BtA-responsive 1 Std. Mean Difference (Fixed, 95% CI) 0.92 [0.50, 1.34]
15.2 BtA-non-responsive 1 Std. Mean Difference (Fixed, 95% CI) 1.01 [0.53, 1.48]
16 Cervical dystonia severity:
change from baseline to week 4
as assessed with TWSTRS
2 Mean Difference (Fixed, 95% CI) 2.43 [1.24, 3.63]
17 Cervical dystonia severity:
change from baseline to week
4 as assessed with TWSTRS -
doses subgroup analysis
3 Mean Difference (Fixed, 95% CI) Subtotals only
17.1 2500 units 2 Mean Difference (Fixed, 95% CI) 1.9 [0.55, 3.25]
17.2 5000 units 2 Mean Difference (Fixed, 95% CI) 2.51 [1.25, 3.77]
17.3 10,000 units 3 Mean Difference (Fixed, 95% CI) 2.96 [1.87, 4.05]
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18 Cervical dystonia associated
disability: change from baseline
to week 4 as assessed with
TWSTRS
2 Mean Difference (Fixed, 95% CI) 2.29 [1.04, 3.54]
19 Cervical dystonia associated
disability: change from baseline
to week 4 as assessed with
TWSTRS - doses subgroup
analysis
3 Mean Difference (Fixed, 95% CI) Subtotals only
19.1 2500 units 2 Mean Difference (Fixed, 95% CI) 2.32 [0.86, 3.78]
19.2 5000 units 2 Mean Difference (Fixed, 95% CI) 2.06 [0.55, 3.57]
19.3 10,000 units 3 Mean Difference (Fixed, 95% CI) 3.22 [2.09, 4.35]
20 Proportion of withdrawals due
to adverse events
4 440 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.19, 4.06]
21 Adverse events: dry mouth 4 438 Risk Ratio (M-H, Fixed, 95% CI) 7.65 [2.75, 21.32]
22 Adverse events: dysphagia 4 438 Risk Ratio (M-H, Fixed, 95% CI) 6.78 [2.42, 19.05]
23 Adverse events: dry mouth -
doses subgroup analysis
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 2500 U 2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.06, 14.78]
23.2 5000 U 3 198 Risk Ratio (M-H, Fixed, 95% CI) 3.94 [0.87, 17.86]
23.3 10,000 U 4 274 Risk Ratio (M-H, Fixed, 95% CI) 11.47 [3.95, 33.30]
24 Adverse events: dysphagia -
doses subgroup analysis
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
24.1 2500 U 2 128 Risk Ratio (M-H, Fixed, 95% CI) 6.79 [0.86, 53.63]
24.2 5000 U 3 198 Risk Ratio (M-H, Fixed, 95% CI) 5.50 [1.25, 24.17]
24.3 10,000 U 4 274 Risk Ratio (M-H, Fixed, 95% CI) 9.19 [3.38, 25.01]
25 Adverse events: infection 3 308 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.38, 3.38]
26 Adverse events: neck pain
secondary to CD
3 308 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.67, 1.73]
27 Adverse events: injection site
pain
4 438 Risk Ratio (M-H, Fixed, 95% CI) 1.39 [0.73, 2.66]
28 Adverse events: nausea 2 199 Risk Ratio (M-H, Fixed, 95% CI) 2.06 [0.68, 6.28]
29 Adverse events: headache 3 361 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.82, 4.41]
30 Adverse events: flu syndrome 3 361 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.23, 8.92]
31 Adverse events: pain 2 231 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.51, 2.62]
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Analysis 1.1. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 1 Overall cervical dystonia
improvement as assessed with TWSTRS: change from baseline to week 4.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 1 Overall cervical dystonia improvement as assessed with TWSTRS: change from baseline to week 4
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Brashear 1999 (1) 6.2164 (2.2359) 26.0 % 6.22 [ 1.83, 10.60 ]
Brin 1999 (2) 9 (2.3147) 24.3 % 9.00 [ 4.46, 13.54 ]
Kaji 2013 (3) 5.9825 (1.6196) 49.6 % 5.98 [ 2.81, 9.16 ]
Total (95% CI) 100.0 % 6.78 [ 4.54, 9.01 ]
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 5.94 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Placebo Favours BtB
(1) TWSTRS, week 4, pooled SD
(2) TWSTRS, week 4, pooled SD
(3) TWSTRS, week 4
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Analysis 1.2. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 2 Overall cervical dystonia
improvement as assessed with TWSTRS: change from baseline to week 4 - Doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 2 Overall cervical dystonia improvement as assessed with TWSTRS: change from baseline to week 4 - Doses subgroup analysis
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 2500 units
Lew 1997 (1) 8.3 (2.5084) 43.9 % 8.30 [ 3.38, 13.22 ]
Kaji 2013 (2) 5.9 (2.2204) 56.1 % 5.90 [ 1.55, 10.25 ]
Subtotal (95% CI) 100.0 % 6.95 [ 3.70, 10.21 ]
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 4.18 (P = 0.000029)
2 5000 units
Lew 1997 (3) 9.2 (2.4971) 30.5 % 9.20 [ 4.31, 14.09 ]
Brashear 1999 (4) 5 (2.774) 24.7 % 5.00 [ -0.44, 10.44 ]
Kaji 2013 (5) 4.6 (2.0616) 44.8 % 4.60 [ 0.56, 8.64 ]
Subtotal (95% CI) 100.0 % 6.10 [ 3.40, 8.81 ]
Heterogeneity: Chi2 = 2.23, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 4.42 (P < 0.00001)
3 10,000 units
Lew 1997 (6) 13.1 (3.1349) 14.9 % 13.10 [ 6.96, 19.24 ]
Brin 1999 (7) 9 (2.3147) 27.4 % 9.00 [ 4.46, 13.54 ]
Brashear 1999 (8) 7.4 (2.5132) 23.2 % 7.40 [ 2.47, 12.33 ]
Kaji 2013 (9) 7.5 (2.0616) 34.5 % 7.50 [ 3.46, 11.54 ]
Subtotal (95% CI) 100.0 % 8.72 [ 6.35, 11.10 ]
Heterogeneity: Chi2 = 2.59, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 7.20 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.15, df = 2 (P = 0.34), I2 =7%
-20 -10 0 10 20
Favours Placebo Favours BtB
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(1) TWSTRS, week 4
(2) TWSTRS, week 4
(3) TWSTRS, week 4
(4) TWSTRS, week 4, pooled SD
(5) TWSTRS, week 4
(6) TWSTRS, week 4
(7) TWSTRS, week 4, pooled SD
(8) TWSTRS, week 4, pooled SD
(9) TWSTRS, week 4
Analysis 1.3. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 3 Overall cervical dystonia
improvement as assessed with TWSTRS: change from baseline to week 4 - BtA-responsive vs BtA-non-
responsive subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 3 Overall cervical dystonia improvement as assessed with TWSTRS: change from baseline to week 4 - BtA-responsive vs BtA-non-responsive subgroup
analysis
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 BtA-responsive
Brashear 1999 9 (2.3147) 48.3 % 9.00 [ 4.46, 13.54 ]
Subtotal (95% CI) 48.3 % 9.00 [ 4.46, 13.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.89 (P = 0.00010)
2 BtA-non-responsive
Brin 1999 6.2164 (2.2357) 51.7 % 6.22 [ 1.83, 10.60 ]
Subtotal (95% CI) 51.7 % 6.22 [ 1.83, 10.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.78 (P = 0.0054)
Total (95% CI) 100.0 % 7.56 [ 4.41, 10.71 ]
Heterogeneity: Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 4.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.75, df = 1 (P = 0.39), I2 =0.0%
-20 -10 0 10 20
Favours Placebo Favours BtB
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Analysis 1.4. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 4 Proportion of participants with
adverse events.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 4 Proportion of participants with adverse events
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brin 1999 39/39 32/38 45.0 % 1.19 [ 1.03, 1.37 ]
Brashear 1999 62/73 30/36 55.0 % 1.02 [ 0.86, 1.21 ]
Total (95% CI) 112 74 100.0 % 1.09 [ 0.97, 1.23 ]
Total events: 101 (BtB), 62 (Placebo)
Heterogeneity: Chi2 = 1.80, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours BtB Favours Placebo
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Analysis 1.5. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 5 Proportion of participants with
adverse events - doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 5 Proportion of participants with adverse events - doses subgroup analysis
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 5000 U
Brin 1999 32/36 30/36 100.0 % 1.07 [ 0.89, 1.29 ]
Subtotal (95% CI) 36 36 100.0 % 1.07 [ 0.89, 1.29 ]
Total events: 32 (BtB), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 10,000 U
Brashear 1999 30/37 30/36 42.4 % 0.97 [ 0.79, 1.20 ]
Brin 1999 39/39 32/38 57.6 % 1.19 [ 1.03, 1.37 ]
Subtotal (95% CI) 76 74 100.0 % 1.09 [ 0.89, 1.33 ]
Total events: 69 (BtB), 62 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
0.5 0.7 1 1.5 2
Favours BtB Favours Placebo
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Analysis 1.6. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 6 Proportion of participants with
adverse events - BtA-responsive vs BtA-non-responsive subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 6 Proportion of participants with adverse events - BtA-responsive vs BtA-non-responsive subgroup analysis
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 BtA-responsive
Brashear 1999 30/37 30/36 100.0 % 0.97 [ 0.79, 1.20 ]
Subtotal (95% CI) 37 36 100.0 % 0.97 [ 0.79, 1.20 ]
Total events: 30 (BtB), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 BtA-non-responsive
Brin 1999 39/39 32/38 100.0 % 1.19 [ 1.03, 1.37 ]
Subtotal (95% CI) 39 38 100.0 % 1.19 [ 1.03, 1.37 ]
Total events: 39 (BtB), 32 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Chi2 = 2.25, df = 1 (P = 0.13), I2 =55%
0.5 0.7 1 1.5 2
Favours BtB Favours Placebo
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Analysis 1.7. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 7 Subjective change as assessed
by the participant at week 4.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 7 Subjective change as assessed by the participant at week 4
Study or subgroup BtB Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brashear 1999 (1) 73 62.6274 (21.3939) 36 43.6 (21.7) 35.4 % 0.88 [ 0.46, 1.30 ]
Brin 1999 (2) 39 60.2 (22.9) 38 39.5 (16.9) 27.1 % 1.02 [ 0.54, 1.49 ]
Kaji 2013 (3) 97 11.6876 (16.1591) 33 -0.4 (18.3826) 37.5 % 0.72 [ 0.31, 1.12 ]
Total (95% CI) 209 107 100.0 % 0.86 [ 0.61, 1.10 ]
Heterogeneity: Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 6.77 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Placebo Favours BtB
(1) PGAC, week 4
(2) PGAC, week 4
(3) PGVAS, week 4
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Analysis 1.8. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 8 Subjective change as assessed
by the clinician at week 4.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 8 Subjective change as assessed by the clinician at week 4
Study or subgroup BtB Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brashear 1999 (1) 73 64.7425 (16.9058) 36 52 (17.5) 35.9 % 0.74 [ 0.33, 1.15 ]
Brin 1999 (2) 39 60.6 (14.4) 38 47.9 (10.7) 27.0 % 0.99 [ 0.51, 1.46 ]
Kaji 2013 (3) 97 12.8113 (15.8774) 33 2 (12.638) 37.1 % 0.71 [ 0.31, 1.11 ]
Total (95% CI) 209 107 100.0 % 0.80 [ 0.55, 1.04 ]
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 6.33 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Placebo Favours BtB
(1) PIGAC, week 4
(2) PIGAC, week 4
(3) IGVAS ,week 4
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Analysis 1.9. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 9 Subjective change as assessed
by the participant at week 4 - doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 9 Subjective change as assessed by the participant at week 4 - doses subgroup analysis
Study or subgroup BtB Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2500 U
Kaji 2013 (1) 34 61.9 (15.2) 33 49.6 (18.4) 100.0 % 12.30 [ 4.21, 20.39 ]
Subtotal (95% CI) 34 33 100.0 % 12.30 [ 4.21, 20.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
2 5000 U
Brashear 1999 (2) 36 59.9 (16.8) 36 52 (17.5) 51.0 % 7.90 [ -0.02, 15.82 ]
Kaji 2013 (3) 32 61.2 (14.7) 33 49.6 (18.4) 49.0 % 11.60 [ 3.52, 19.68 ]
Subtotal (95% CI) 68 69 100.0 % 9.71 [ 4.05, 15.37 ]
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.36 (P = 0.00077)
3 10,000 U
Brashear 1999 (4) 37 64.2 (16) 36 52 (17.5) 38.8 % 12.20 [ 4.50, 19.90 ]
Brin 1999 (5) 39 60.2 (22.9) 38 39.5 (16.9) 28.5 % 20.70 [ 11.73, 29.67 ]
Kaji 2013 (6) 31 63.3 (15.8) 33 49.6 (18.4) 32.7 % 13.70 [ 5.31, 22.09 ]
Subtotal (95% CI) 107 107 100.0 % 15.12 [ 10.32, 19.91 ]
Heterogeneity: Chi2 = 2.15, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 6.18 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.05, df = 2 (P = 0.36), I2 =3%
-20 -10 0 10 20
Favours Placebo Favours BtB
(1) IGVAS, week 4
(2) IGAC, week 4
(3) IGVAS, week 4
(4) IGAC, week 4
(5) PGAC, week 4
(6) IGVAS, week 4
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Analysis 1.10. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 10 Subjective change as assessed
by the clinician at week 4 - doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 10 Subjective change as assessed by the clinician at week 4 - doses subgroup analysis
Study or subgroup BtB Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 2500 U
Kaji 2013 (1) 34 60.6 (16.8) 33 52 (12.8) 100.0 % 8.60 [ 1.46, 15.74 ]
Subtotal (95% CI) 34 33 100.0 % 8.60 [ 1.46, 15.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
2 5000 U
Brashear 1999 (2) 36 65.3 (18) 36 52 (17.5) 40.1 % 13.30 [ 5.10, 21.50 ]
Kaji 2013 (3) 32 61.2 (14.7) 33 52 (12.8) 59.9 % 9.20 [ 2.49, 15.91 ]
Subtotal (95% CI) 68 69 100.0 % 10.84 [ 5.65, 16.04 ]
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 4.09 (P = 0.000043)
3 10,000 U
Brashear 1999 (4) 37 64.2 (16) 36 52 (17.5) 24.8 % 12.20 [ 4.50, 19.90 ]
Kaji 2013 (5) 31 66.9 (15.8) 33 52 (12.8) 29.4 % 14.90 [ 7.83, 21.97 ]
Brin 1999 (6) 39 60.6 (14.4) 38 47.9 (10.7) 45.9 % 12.70 [ 7.04, 18.36 ]
Subtotal (95% CI) 107 107 100.0 % 13.22 [ 9.39, 17.05 ]
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 6.76 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.43, df = 2 (P = 0.49), I2 =0.0%
-100 -50 0 50 100
Favours Placebo Favours BtB
(1) IGVAS, week 4
(2) IGAC, week 4
(3) IGVAS, week 4
(4) IGAC, week 4
(5) IGVAS, week 4
(6) PIGAC, week 4
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Analysis 1.11. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 11 Subjective change as assessed
by the participant at week 4 - BtA-responsive vs BtA-non-responsive subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 11 Subjective change as assessed by the participant at week 4 - BtA-responsive vs BtA-non-responsive subgroup analysis
Study or subgroup BtB Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BtA-responsive
Brashear 1999 (1) 73 62.6274 (21.3939) 36 43.6 (21.7) 52.0 % 19.03 [ 10.41, 27.65 ]
Subtotal (95% CI) 73 36 52.0 % 19.03 [ 10.41, 27.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
2 BtA-non-responsive
Brin 1999 (2) 39 60.2 (22.9) 38 39.5 (16.9) 48.0 % 20.70 [ 11.73, 29.67 ]
Subtotal (95% CI) 39 38 48.0 % 20.70 [ 11.73, 29.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.52 (P < 0.00001)
Total (95% CI) 112 74 100.0 % 19.83 [ 13.61, 26.05 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 6.25 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
-20 -10 0 10 20
Favours Placebo Favours BtB
(1) PGAC, week 4
(2) PGAC, week 4
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Analysis 1.12. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 12 Subjective change as assessed
by the clinician at week 4 - BtA-non-responsive vs -responsive subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 12 Subjective change as assessed by the clinician at week 4 - BtA-non-responsive vs -responsive subgroup analysis
Study or subgroup BtB Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 BtA-responsive
Brashear 1999 (1) 73 64.7425 (16.9058) 36 52 (17.5) 100.0 % 12.74 [ 5.83, 19.65 ]
Subtotal (95% CI) 73 36 100.0 % 12.74 [ 5.83, 19.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.62 (P = 0.00030)
2 BtA-non-responsive
Brin 1999 (2) 39 60.6 (14.4) 38 47.9 (10.7) 100.0 % 12.70 [ 7.04, 18.36 ]
Subtotal (95% CI) 39 38 100.0 % 12.70 [ 7.04, 18.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.40 (P = 0.000011)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
-20 -10 0 10 20
Favours Placebo Favours BtB
(1) PIGAC, week 4
(2) PIGAC, week 4
51Botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.13. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 13 Cervical dystonia associated
pain: change from baseline to week 4 as assessed with TWSTRS.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 13 Cervical dystonia associated pain: change from baseline to week 4 as assessed with TWSTRS
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Brin 1999 (1) 3.4 (0.9154) 27.8 % 3.40 [ 1.61, 5.19 ]
Kaji 2013 (2) 1.7392 (0.5675) 72.2 % 1.74 [ 0.63, 2.85 ]
Total (95% CI) 100.0 % 2.20 [ 1.25, 3.15 ]
Heterogeneity: Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 4.56 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Placebo Favours BtB
(1) TWSTRS, week 4, pooled SD
(2) TWSTRS, week 4
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Analysis 1.14. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 14 Cervical dystonia associated
pain: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 14 Cervical dystonia associated pain: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 2500 units
Kaji 2013 (1) 2.1 (0.8062) 62.7 % 2.10 [ 0.52, 3.68 ]
Lew 1997 (2) 3.4 (1.0457) 37.3 % 3.40 [ 1.35, 5.45 ]
Subtotal (95% CI) 100.0 % 2.58 [ 1.33, 3.84 ]
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 4.05 (P = 0.000052)
2 5000 units
Kaji 2013 (3) 1.2 (0.8062) 59.5 % 1.20 [ -0.38, 2.78 ]
Lew 1997 (4) 3.3 (0.977) 40.5 % 3.30 [ 1.39, 5.21 ]
Subtotal (95% CI) 100.0 % 2.05 [ 0.83, 3.27 ]
Heterogeneity: Chi2 = 2.75, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 3.30 (P = 0.00097)
3 10,000 units
Brin 1999 (5) 3.4 (0.9154) 35.8 % 3.40 [ 1.61, 5.19 ]
Kaji 2013 (6) 1.9 (0.8062) 46.2 % 1.90 [ 0.32, 3.48 ]
Lew 1997 5.4 (1.2922) 18.0 % 5.40 [ 2.87, 7.93 ]
Subtotal (95% CI) 100.0 % 3.07 [ 1.99, 4.14 ]
Heterogeneity: Chi2 = 5.49, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 5.60 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.51, df = 2 (P = 0.47), I2 =0.0%
-10 -5 0 5 10
Favours Placebo Favours BtB
(1) TWSTRS, week 4
(2) TWSTRS, week 4
(3) TWSTRS, week 4
(4) TWSTRS, week 4
(5) TWSTRS, week 4, pooled SD
(6) TWSTRS, week 4
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Analysis 1.15. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 15 Cervical dystonia associated
pain: change from baseline to week 4 as assessed with validated scales - BtA-responsive vs BtA-non-responsive
subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 15 Cervical dystonia associated pain: change from baseline to week 4 as assessed with validated scales - BtA-responsive vs BtA-non-responsive subgroup
analysis
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 BtA-responsive
Brashear 1999 (1) 0.9206 (0.2133) 56.4 % 0.92 [ 0.50, 1.34 ]
Subtotal (95% CI) 56.4 % 0.92 [ 0.50, 1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.32 (P = 0.000016)
2 BtA-non-responsive
Brin 1999 (2) 1.0088 (0.2427) 43.6 % 1.01 [ 0.53, 1.48 ]
Subtotal (95% CI) 43.6 % 1.01 [ 0.53, 1.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.16 (P = 0.000032)
Total (95% CI) 100.0 % 0.96 [ 0.65, 1.27 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 5.99 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.78), I2 =0.0%
-4 -2 0 2 4
Favours Placebo Favours BtB
(1) Patient analog pain assessment, week 4, pooled SD
(2) TWSTRS pain subscore, week 4, pooled SD
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Analysis 1.16. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 16 Cervical dystonia severity:
change from baseline to week 4 as assessed with TWSTRS.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 16 Cervical dystonia severity: change from baseline to week 4 as assessed with TWSTRS
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Brin 1999 (1) 2.6 (1.0528) 33.4 % 2.60 [ 0.54, 4.66 ]
Kaji 2013 (2) 2.3495 (0.7457) 66.6 % 2.35 [ 0.89, 3.81 ]
Total (95% CI) 100.0 % 2.43 [ 1.24, 3.63 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.00 (P = 0.000064)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Placebo Favours BtB
(1) TWSTRS, week 4, pooled SD
(2) TWSTRS, week 4
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Analysis 1.17. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 17 Cervical dystonia severity:
change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 17 Cervical dystonia severity: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 2500 units
Kaji 2013 (1) 1.9 (1) 47.7 % 1.90 [ -0.06, 3.86 ]
Lew 1997 (2) 1.9 (0.9542) 52.3 % 1.90 [ 0.03, 3.77 ]
Subtotal (95% CI) 100.0 % 1.90 [ 0.55, 3.25 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.75 (P = 0.0059)
2 5000 units
Kaji 2013 (3) 2.1 (0.922) 48.9 % 2.10 [ 0.29, 3.91 ]
Lew 1997 (4) 2.9 (0.9013) 51.1 % 2.90 [ 1.13, 4.67 ]
Subtotal (95% CI) 100.0 % 2.51 [ 1.25, 3.77 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.000099)
3 10,000 units
Brin 1999 (5) 2.6 (1.0528) 27.9 % 2.60 [ 0.54, 4.66 ]
Kaji 2013 (6) 3.1 (1) 30.9 % 3.10 [ 1.14, 5.06 ]
Lew 1997 (7) 3.1 (0.8656) 41.2 % 3.10 [ 1.40, 4.80 ]
Subtotal (95% CI) 100.0 % 2.96 [ 1.87, 4.05 ]
Heterogeneity: Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.33 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.43, df = 2 (P = 0.49), I2 =0.0%
-10 -5 0 5 10
Favours Placebo Favours BtB
(1) TWSTRS, week 4
(2) TWSTRS, week 4
(3) TWSTRS, week 4
(4) TWSTRS, week 4
(5) TWSTRS, week 4, pooled SD
(6) TWSTRS, week 4
(7) TWSTRS, week 4
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Analysis 1.18. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 18 Cervical dystonia associated
disability: change from baseline to week 4 as assessed with TWSTRS.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 18 Cervical dystonia associated disability: change from baseline to week 4 as assessed with TWSTRS
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Brin 1999 (1) 3 (1.0652) 35.7 % 3.00 [ 0.91, 5.09 ]
Kaji 2013 (2) 1.8938 (0.7931) 64.3 % 1.89 [ 0.34, 3.45 ]
Total (95% CI) 100.0 % 2.29 [ 1.04, 3.54 ]
Heterogeneity: Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00032)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Placebo Favours BtB
(1) TWSTRS, week 4, pooled SD
(2) TWSTRS, week 4
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Analysis 1.19. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 19 Cervical dystonia associated
disability: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 19 Cervical dystonia associated disability: change from baseline to week 4 as assessed with TWSTRS - doses subgroup analysis
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 2500 units
Kaji 2013 (1) 1.9 (0.922) 65.0 % 1.90 [ 0.09, 3.71 ]
Lew 1997 (2) 3.1 (1.256) 35.0 % 3.10 [ 0.64, 5.56 ]
Subtotal (95% CI) 100.0 % 2.32 [ 0.86, 3.78 ]
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.12 (P = 0.0018)
2 5000 units
Kaji 2013 (3) 1.3 (1.063) 52.7 % 1.30 [ -0.78, 3.38 ]
Lew 1997 (4) 2.9 (1.1214) 47.3 % 2.90 [ 0.70, 5.10 ]
Subtotal (95% CI) 100.0 % 2.06 [ 0.55, 3.57 ]
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 2.67 (P = 0.0077)
3 10,000 units
Brin 1999 (5) 3 (1.0652) 29.2 % 3.00 [ 0.91, 5.09 ]
Kaji 2013 (6) 2.5 (0.8602) 44.7 % 2.50 [ 0.81, 4.19 ]
Lew 1997 (7) 4.7 (1.1247) 26.1 % 4.70 [ 2.50, 6.90 ]
Subtotal (95% CI) 100.0 % 3.22 [ 2.09, 4.35 ]
Heterogeneity: Chi2 = 2.47, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 5.60 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.77, df = 2 (P = 0.41), I2 =0.0%
-4 -2 0 2 4
Favours Placebo Favours BtB
(1) TWSTRS, week 4
(2) TWSTRS, week 4
(3) TWSTRS, week 4
(4) TWSTRS, week 4
(5) TWSTRS, week 4, pooled SD
(6) TWSTRS, week 4
(7) TWSTRS, week 4
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Analysis 1.20. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 20 Proportion of withdrawals
due to adverse events.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 20 Proportion of withdrawals due to adverse events
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lew 1997 (1) 0/92 0/30 Not estimable
Brin 1999 (2) 0/39 1/38 42.5 % 0.33 [ 0.01, 7.74 ]
Brashear 1999 (3) 2/73 1/38 36.8 % 1.04 [ 0.10, 11.12 ]
Kaji 2013 (4) 2/97 0/33 20.8 % 1.73 [ 0.09, 35.23 ]
Total (95% CI) 301 139 100.0 % 0.88 [ 0.19, 4.06 ]
Total events: 4 (BtB), 2 (Placebo)
Heterogeneity: Chi2 = 0.59, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours BtB Favours Placebo
(1) No withdrawals
(2) 1 patients withdraw treatment due to adverse event
(3) 2 patients (1 BtB and 1 placebo) withdraw treatment due to lack of effect, 1 patient (BtB) withdraw treatment due to serious adverse event
(4) 2 patients withdraw treatment due to lack of effect
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Analysis 1.21. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 21 Adverse events: dry mouth.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 21 Adverse events: dry mouth
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brashear 1999 14/73 1/36 29.1 % 6.90 [ 0.94, 50.46 ]
Brin 1999 17/39 1/38 22.0 % 16.56 [ 2.32, 118.38 ]
Kaji 2013 4/97 0/33 16.1 % 3.12 [ 0.17, 56.50 ]
Lew 1997 14/92 1/30 32.8 % 4.57 [ 0.63, 33.28 ]
Total (95% CI) 301 137 100.0 % 7.65 [ 2.75, 21.32 ]
Total events: 49 (BtB), 3 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.000099)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
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Analysis 1.22. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 22 Adverse events: dysphagia.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 22 Adverse events: dysphagia
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lew 1997 16/92 0/30 15.4 % 11.00 [ 0.68, 178.02 ]
Brin 1999 11/39 2/38 41.7 % 5.36 [ 1.27, 22.59 ]
Brashear 1999 12/73 1/36 27.6 % 5.92 [ 0.80, 43.75 ]
Kaji 2013 11/97 0/33 15.3 % 7.98 [ 0.48, 131.80 ]
Total (95% CI) 301 137 100.0 % 6.78 [ 2.42, 19.05 ]
Total events: 50 (BtB), 3 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.64 (P = 0.00028)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours BtB Favours Placebo
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Analysis 1.23. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 23 Adverse events: dry mouth -
doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 23 Adverse events: dry mouth - doses subgroup analysis
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2500 U
Kaji 2013 0/34 0/33 Not estimable
Lew 1997 1/31 1/30 100.0 % 0.97 [ 0.06, 14.78 ]
Subtotal (95% CI) 65 63 100.0 % 0.97 [ 0.06, 14.78 ]
Total events: 1 (BtB), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
2 5000 U
Brashear 1999 5/36 1/36 49.6 % 5.00 [ 0.61, 40.70 ]
Kaji 2013 0/32 0/33 Not estimable
Lew 1997 3/31 1/30 50.4 % 2.90 [ 0.32, 26.38 ]
Subtotal (95% CI) 99 99 100.0 % 3.94 [ 0.87, 17.86 ]
Total events: 8 (BtB), 2 (Placebo)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
3 10,000 U
Brashear 1999 9/37 1/36 28.9 % 8.76 [ 1.17, 65.64 ]
Brin 1999 17/39 1/38 28.8 % 16.56 [ 2.32, 118.38 ]
Kaji 2013 4/31 0/33 13.8 % 9.56 [ 0.54, 170.62 ]
Lew 1997 10/30 1/30 28.5 % 10.00 [ 1.36, 73.33 ]
Subtotal (95% CI) 137 137 100.0 % 11.47 [ 3.95, 33.30 ]
Total events: 40 (BtB), 3 (Placebo)
Heterogeneity: Chi2 = 0.24, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 4.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.39, df = 2 (P = 0.18), I2 =41%
0.001 0.01 0.1 1 10 100 1000
Favours BtB Favours Placebo
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Analysis 1.24. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 24 Adverse events: dysphagia -
doses subgroup analysis.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 24 Adverse events: dysphagia - doses subgroup analysis
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 2500 U
Lew 1997 5/31 0/30 50.0 % 10.66 [ 0.61, 184.70 ]
Kaji 2013 1/34 0/33 50.0 % 2.91 [ 0.12, 69.08 ]
Subtotal (95% CI) 65 63 100.0 % 6.79 [ 0.86, 53.63 ]
Total events: 6 (BtB), 0 (Placebo)
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 5000 U
Lew 1997 3/31 0/30 25.4 % 6.78 [ 0.37, 125.95 ]
Brashear 1999 4/36 1/36 50.0 % 4.00 [ 0.47, 34.07 ]
Kaji 2013 3/32 0/33 24.6 % 7.21 [ 0.39, 134.29 ]
Subtotal (95% CI) 99 99 100.0 % 5.50 [ 1.25, 24.17 ]
Total events: 10 (BtB), 1 (Placebo)
Heterogeneity: Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
3 10,000 U
Lew 1997 10/30 0/30 12.4 % 21.00 [ 1.29, 342.93 ]
Brin 1999 11/39 2/38 50.3 % 5.36 [ 1.27, 22.59 ]
Brashear 1999 8/37 1/36 25.2 % 7.78 [ 1.02, 59.12 ]
Kaji 2013 7/31 0/33 12.0 % 15.94 [ 0.95, 267.84 ]
Subtotal (95% CI) 137 137 100.0 % 9.19 [ 3.38, 25.01 ]
Total events: 36 (BtB), 3 (Placebo)
Heterogeneity: Chi2 = 1.05, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
Test for subgroup differences: Chi2 = 0.33, df = 2 (P = 0.85), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours BtB Favours Placebo
63Botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.25. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 25 Adverse events: infection.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 25 Adverse events: infection
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brashear 1999 12/73 10/36 47.0 % 0.59 [ 0.28, 1.24 ]
Brin 1999 8/39 6/38 40.9 % 1.30 [ 0.50, 3.39 ]
Lew 1997 13/92 0/30 12.1 % 9.00 [ 0.55, 147.01 ]
Total (95% CI) 204 104 100.0 % 1.14 [ 0.38, 3.38 ]
Total events: 33 (BtB), 16 (Placebo)
Heterogeneity: Tau2 = 0.52; Chi2 = 5.08, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
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Analysis 1.26. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 26 Adverse events: neck pain
secondary to CD.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 26 Adverse events: neck pain secondary to CD
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brashear 1999 21/73 9/36 46.0 % 1.15 [ 0.59, 2.25 ]
Brin 1999 8/39 8/38 30.9 % 0.97 [ 0.41, 2.33 ]
Lew 1997 13/92 4/30 23.0 % 1.06 [ 0.37, 3.00 ]
Total (95% CI) 204 104 100.0 % 1.08 [ 0.67, 1.73 ]
Total events: 42 (BtB), 21 (Placebo)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
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Analysis 1.27. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 27 Adverse events: injection site
pain.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 27 Adverse events: injection site pain
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brashear 1999 6/73 3/36 27.6 % 0.99 [ 0.26, 3.72 ]
Brin 1999 7/39 3/38 20.9 % 2.27 [ 0.63, 8.15 ]
Kaji 2013 3/97 2/33 20.5 % 0.51 [ 0.09, 2.92 ]
Lew 1997 16/92 3/30 31.1 % 1.74 [ 0.54, 5.56 ]
Total (95% CI) 301 137 100.0 % 1.39 [ 0.73, 2.66 ]
Total events: 32 (BtB), 11 (Placebo)
Heterogeneity: Chi2 = 2.24, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
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Analysis 1.28. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 28 Adverse events: nausea.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 28 Adverse events: nausea
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brin 1999 6/39 3/38 66.8 % 1.95 [ 0.52, 7.24 ]
Lew 1997 7/92 1/30 33.2 % 2.28 [ 0.29, 17.81 ]
Total (95% CI) 131 68 100.0 % 2.06 [ 0.68, 6.28 ]
Total events: 13 (BtB), 4 (Placebo)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
Analysis 1.29. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 29 Adverse events: headache.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 29 Adverse events: headache
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brashear 1999 14/73 3/36 47.1 % 2.30 [ 0.71, 7.50 ]
Kaji 2013 5/97 1/33 17.5 % 1.70 [ 0.21, 14.04 ]
Lew 1997 9/92 2/30 35.4 % 1.47 [ 0.34, 6.42 ]
Total (95% CI) 262 99 100.0 % 1.90 [ 0.82, 4.41 ]
Total events: 28 (BtB), 6 (Placebo)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
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Analysis 1.30. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 30 Adverse events: flu syndrome.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 30 Adverse events: flu syndrome
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brashear 1999 6/73 1/36 30.6 % 2.96 [ 0.37, 23.66 ]
Kaji 2013 12/97 9/33 46.5 % 0.45 [ 0.21, 0.98 ]
Lew 1997 8/92 0/30 22.9 % 5.67 [ 0.34, 95.36 ]
Total (95% CI) 262 99 100.0 % 1.44 [ 0.23, 8.92 ]
Total events: 26 (BtB), 10 (Placebo)
Heterogeneity: Tau2 = 1.71; Chi2 = 6.07, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
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Analysis 1.31. Comparison 1 Botulinum toxin type B vs Placebo, Outcome 31 Adverse events: pain.
Review: Botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type B vs Placebo
Outcome: 31 Adverse events: pain
Study or subgroup BtB Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brashear 1999 11/73 5/36 68.9 % 1.08 [ 0.41, 2.89 ]
Lew 1997 8/92 2/30 31.1 % 1.30 [ 0.29, 5.81 ]
Total (95% CI) 165 66 100.0 % 1.15 [ 0.51, 2.62 ]
Total events: 19 (BtB), 7 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours Placebo
A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
BtA-non-responsive People who do not experience the expected benefit from treatment with botulinum
toxin type A
Cervical dystonia or spasmodic toricollis It is a common movement disorder in which people have abnormal movements or
postures of the head and neck that they cannot control. It is frequently accompanied
by social embarrassment and pain
Chemodenervation It is the process by which botulinum toxin causes muscular paralysis. Altought all the
anatomical elements necessary for muscular control are intact (i.e. nerve, synapse and
muscle), there is a chemical process that disables the transmission of the transmission
of the electrical signal from the nerve to the muscle
Dysphagia A discomfort or difficulty when swallowing.
Electromyography It is an exam that displays the electrical activity ofmuscles using pieces ofmetal attached
to the skin or inserted into the muscle
Non-naive People who have been treated in the past with botulinum toxin
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Table 1. Glossary of terms (Continued)
Voluntary action Movements that we are able to control, start and stop when we want to
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Botulinum Toxins] explode all trees
#2 MeSH descriptor: [Botulinum Toxins, Type A] explode all trees
#3 (botul* near/2 tox*):ti,ab
#4 (botox or dysport or xeomin or myobloc or rimabotulinum* or abobotuli* or onabotulinum* or oculinum or
purtox or CNBTX or Neuronox):ti,ab
#5 {or #1-#4}
#6 MeSH descriptor: [Animals] explode all trees
#7 MeSH descriptor: [Humans] explode all trees
#8#6 not #7
#9#5 not #8
#10 (cervic* near/2 dysto*):ti,ab
#11 blepharosp*:ti,ab
#12 (hem* near/2 spasm*):ti,ab
#13 (meige and (dysto* or syndrom*)):ti,ab
#14 (crani* near/2 dysto*):ti,ab
#15 (foca* near/2 dysto*):ti,ab
#16 (write* and (cramp* or dysto*)):ti,ab
#17 torticol*:ti,ab
#18 MeSH descriptor: [Dystonic Disorders] explode all trees
#19 MeSH descriptor: [Dystonia] explode all trees
#20 MeSH descriptor: [Torticollis] explode all trees
#21 MeSH descriptor: [Blepharospasm] explode all trees
#22 MeSH descriptor: [Meige Syndrome] explode all trees
#23 MeSH descriptor: [Hemifacial Spasm] explode all trees
#24 {or #10-#23}
#25 MeSH descriptor: [Animals] explode all trees
#26 MeSH descriptor: [Humans] explode all trees
#27#25 not #26
#28#24 not #27
#29#9 and #28, in Trials
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Appendix 2. MEDLINE search strategy
#1 randomized controlled trial.pt.
#2 controlled clinical trial.pt.
#3 randomized.ab.
#4 placebo.ab.
#5 clinical trials as topic.sh.
#6 randomly.ab.
#7 trial.ti.
#8 1 or 2 or 3 or 4 or 5 or 6 or 7
#9 exp animals/ not humans.sh.
#10 ((randomized controlled trial or controlled clinical trial or randomized or placebo or clinical trials as topic or
randomly or trial) not (animals not humans)).af,pt.
#11 exp botulinum toxins/
#12 exp botulinum toxins, type A/
#13 (botul$ adj2 tox$).ti,ab.
#14 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or
purtox or CNBTX or Neuronox).ti,ab.
#15 11 or 12 or 13 or 14
#16 exp animals/ not humans/
#17 ((botulinum toxins or botulinum toxins, type A or (botul$ adj2 tox$) or (botox or dysport or xeomin or
myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX or Neuronox)) not
(animals not humans)).af.
#18 (cervic$ adj2 dysto$).ti,ab.
#19 blepharosp$.ti,ab.
#20 (hem$ adj2 spasm$).ti,ab.
#21 (meige and (dysto$ or syndrom$)).ti,ab.
#22 (crani$ adj2 dysto$).ti,ab.
#23 (foca$ adj2 dysto$).ti,ab.
#24 (write$ and (cramp$ or dysto$)).ti,ab.
#25 torticol$.ti,ab.
#26 exp dystonic disorders/
#27 exp dystonia/
#28 exp torticollis/
#29 exp blepharospasm/
#30 exp meige syndrome/
#31 exp hemifacial spasm/
#32 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
#33 exp animals/ not humans/
#34 (((cervic$ adj2 dysto$) or blepharosp$ or (hem$ adj2 spasm$) or (meige and (dysto$ or syndrom$)) or
(crani$ adj2 dysto$) or (foca$ adj2 dysto$) or (write$ and (cramp$ or dysto$)) or torticol$ or dystonic disorders or
dystonia or torticollis or blepharospasm or meige syndrome or hemifacial spasm) not (animals not humans)).af.
#35 10 and 17 and 34
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Appendix 3. EMBASE search strategy
#1 random$.tw.
#2 clinical trial:.mp.
#3 placebo$.mp.
#4 double-blind$.tw.
#5 1 or 2 or 3 or 4
#6 5
#7 limit 6 to human
#8 (cervic$ adj2 dysto$).ti,ab.
#9 blepharosp$.ti,ab.
#10 (hem$ adj2 spasm$).ti,ab.
#11 (meige and (dysto$ or syndrom$)).ti,ab.
#12 (crani$ adj2 dysto$).ti,ab.
#13 (foca$ adj2 dysto$).ti,ab.
#14 (write$ and (cramp$ or dysto$)).ti,ab.
#15 torticol$.ti,ab.
#16 exp Dystonic Disorders/
#17 exp Dystonia/
#18 exp torticollis/
#19 exp blepharospasm/
#20 exp Meige Syndrome/
#21 exp Hemifacial Spasm/
#22 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
#23 22
#24 limit 23 to human
#25 (botul$ adj2 tox$).ti,ab.
#26 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or
purtox or CNBTX or Neuronox).ti,ab.
#27 exp Botulinum Toxins/
#28 exp Botulinum Toxins, Type A/
#29 25 or 26 or 27 or 28
#30 29
#31 limit 30 to human
#32 7 and 24 and 31
WH A T ’ S N E W
Last assessed as up-to-date: 26 October 2015.
Date Event Description
22 April 2016 New citation required but conclusions have not
changed
New authorship, accumulation of changes, re-assess-
ment and writing according to new quality standards,
addition of a summary of findings table
26 October 2015 New search has been performed A new trial enrolling 230 participants was included in
the meta-analysis and systematic review (Kaji 2013)
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H I S T O R Y
Protocol first published: Issue 3, 2003
Review first published: Issue 1, 2005
Date Event Description
7 October 2008 Amended Converted to new review format.
7 June 2004 New citation required and conclusions have changed Substantive amendment
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D E C L A R A T I O N S O F I N T E R E S T
Costa J, Ferreira JJ, Sampaio C have been investigators in clinical trials sponsored by Elan, Allergan, and Ipsen. Ferreira JJ and Sampaio
C were speakers in symposia promoted by Elan, Allergan, and Ipsen.
Moore AP has received fees from various companies marketing botulinum toxin for speaking at meetings and for advice. His unit has
received funds for research.
S O U R C E S O F S U P P O R T
Internal sources
• Cochrane Movement Disorders, Portugal.
• The Walton Centre for Neurology and Neurosurgery, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For this updated review the study designs accepted were restricted to parallel-group. No changes were made in the type of participants
included or in the interventions allowed.
Adverse events, which were originally a secondary outcome, were included in this updated review as a primary safety outcome. In
this safety analysis we considered also the proportion of participants with the most frequent adverse events, not stated in the original
protocol. Assessments of the duration of effect and proportion of withdrawals due to adverse drug reactions were included as new
secondary outcomes measures.
The search strategy was prolonged from the inception to October 2015.
New approaches were assumed to deal with missing data and unit of analysis issue.
The latest recommended Cochrane tool for assessing risk of bias was used in this review, which was expanded to include two additional
criteria, added by the review authors. Blinding of outcome assessment was analysed in two new subcategories: subjective and objective
assessment.
A ‘Summary of findings for the main comparison’ table was also added.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Botulinum Toxins [∗therapeutic use]; Botulinum Toxins, Type A; Neuromuscular Agents [∗therapeutic use]; Randomized Controlled
Trials as Topic; Torticollis [∗drug therapy]
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MeSH check words
Humans
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